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ABSTRACT 
Complex carbohydrates exist in almost all species of plants, animals and 
microorganisms. Because of their physiochemical properties, they have been 
traditionally applied as emulsifiers and stabilizers in food, cosmetics, textiles and as 
pharmaceutical ingredients.  Complex carbohydrates generally exist as a layer of 
thick, sequential, hydrous polymers consisting of monosaccharides and 
non-carbohydrate substituents such as acetate, pyruvate, and phosphate. While 
complex carbohydrates are generally believed to serve as structural support or energy 
sources for the producing organisms, their potential biomedical properties have been 
less investigated. Our understanding of the biological activities of complex 
carbohydrates is further complicated since most have been tested after only rough 
purification and their structural characteristics need to be further elucidated. In order 
to establish structure-activity relationships for these molecules, careful structural 
studies need to be undertaken. 
 
In Manuscript I, a group of oligosaccharides isolated from North American 
cranberries (Vaccinium macrocarpon) was investigated for their inhibition on the 
biofilm formation by uropathogenic bacterium Escherichia coli CFT073. Most urinary 
tract infections (UTIs) are associated with E. coli that could form biofilm along the 
urinary tract, especially on the bladder wall, to prevent eradication by the urinal and 
immune system. Intake of cranberry juice is traditionally believed to have preventive 
  
effects against UTIs but the molecular mechanism is still unclear. In contrast to the 
role that phenolic secondary metabolites might play in preventing UTIs, carbohydrate 
constituents in cranberry have not been previously investigated. In this study, we 
identified certain oligosaccharides that are capable for reducing biofilm formation by 
uropathogenic E. coli.  
 
In Manuscript II, a chemically characterized oligosaccharide-enriched fraction 
purified from the North American cranberries (Vaccinium macrocarpon) was 
evaluated for its capability of inhibiting the formation of advanced glycation 
end-products (AGEs) and antioxidant effects. AGEs are glycation adducts formed via 
non-enzymatic glycation occurred between carbohydrates and proteins. Long term in 
vivo accumulation of AGEs is involved in many chronic diseases. The 
oligosaccharide-enriched fraction inhibited AGE formation in with comparable 
activity to a synthetic anti-glycating agent. In the 1,1-Diphenyl-2-picryl-hydrazyl 
(DPPH) free radical scavenging assay, Cranf1b-CL showed antioxidant activity 
superior to the synthetic commercial antioxidant, butylated hydroxytoluene. 
 
In Manuscript III, a Rhamnogalacturonan-I type pectic polysaccharide was isolated 
from ginseng root aqueous extract and shown to prevent biofilm formation by P. 
aeruginosa both in vivo and in vitro. Mechanistic study on the polysaccharide 
exhibited its inhibitory effect on the intracellular cyclic di-GMP level of P. aeruginosa, 
  
suggesting that this polysaccharide inhibits the biofilm formation by altering a core 
biochemical signaling process in P. aeruginosa to interrupt the biofilm formation and 
promote the biofilm dispersal.  
 
In Manuscript IV, the polymeric substances from maple syrup were investigated. By 
ethanol precipitation and anion exchange chromatography, polysaccharides including 
inulin, rhamnogalacturonan, arabinogalactan and dextran were extracted and purified, 
among which inulin was isolated from maple syrup for the first time. The structures of 
these polysaccharides were analyzed by glycosyl composition analysis, glycosyl 
linakge analysis and NMR. Further investigations should be focused on the biological 
activities of maple syrup polysaccharides and their contributions to the overall health 
benefits of maple syrup. 
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MANUSCRIPT I 
 
Published in Journal of Functional Foods, 2015, 17, 235-242 
 
Cranberry (Vaccinium macrocarpon) oligosaccharides decrease biofilm formation 
by uropathogenic Escherichia coli 
Jiadong Suna, Jannie P. J. Maraisb, Christina Khoob, Kerry LaPlantec,d, Rebecca M. 
Vejborge, Michael Givskove, Tim Tolker-Nielsene, Navindra P. Seerama,* and David C. 
Rowleya,* 
 
aDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, 
University of Rhode Island, Kingston, RI 02881, USA 
bOcean Spray Cranberries, Inc., One Ocean Spray Drive, Lakeville-Middleboro, MA, 
02349, USA 
cDepartments of Biomedical and Pharmaceutical Sciences and Pharmacy Practice, 
College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA 
dVeterans Affairs Medical Center, Providence, RI, 02908, USA 
eDepartment of Immunology and Microbiology, University of Copenhagen, DK 2200 
Copenhagen N, Denmark. 
 
Corresponding Authors:  
*(N.P.S.) Email: nseeram@uri.edu; (D.C.R.) Email: drowley@uri.edu 
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ABSTRACT 
The preventive effects of the American cranberry (Vaccinium macrocarpon) against 
urinary tract infections are supported by extensive studies which have primarily 
focused on its phenolic constituents. Herein, a phenolic-free carbohydrate fraction 
(designated cranf1b-F2) was purified from cranberry fruit using ion exchange and size 
exclusion chromatography.  MALDI-TOF-MS analysis revealed that the cranf1b-F2 
constituents are predominantly oligosaccharides possessing various degrees of 
polymerisation and further structural analysis (by GC-MS and NMR) revealed mainly 
xyloglucan and arabinan residues. In antimicrobial assays, cranf1b-F2 (at 1.25 mg/mL 
concentration) reduced biofilm production by the uropathogenic Escherichia coli 
CFT073 strain by over 50% but did not inhibit bacterial growth. Cranf1b-F2 (ranging 
from 0.625 - 10 mg/mL) also inhibited biofilm formation of the non-pathogenic E. coli 
MG1655 strain up to 60% in a concentration-dependent manner. These results suggest 
that cranberry oligosaccharides, in addition to its phenolic constituents, may play a 
role in its preventive effects against urinary tract infections.  
 
Keywords:  American cranberry, Vaccinium macrocarpon, phenolic, oligosaccharide, 
biofilm, Escherichia coli 
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1. Introduction 
Urinary tract infections (UTI) commonly occur anywhere from the kidney in the upper 
urinary tract to the bladder in the lower urinary tract.  Although UTIs are generally 
easy to treat with antibiotics, acute infections can be dangerous for elderly, infant and 
immunocompromised patients (Jepson, Williams, & Craig, 2012). Some UTI patients 
can experience frequent recurrent infections and increased susceptibility to drug 
resistant uropathogens (Jepson et al., 2012; Reid et al., 2001). Over 80% of UTIs are 
associated with Escherichia coli, which may be transmitted from the bowel to urethra.  
Biofilms that form on the bladder wall help prevent the bacteria from being eradicated 
by the immune system and antibiotics (Anderson et al., 2003; Moreno et al., 2008). 
Evidence suggests that consumption of the American cranberry (Vaccinium 
macrocarpon Aiton) juice can inhibit the presence of bacteria in urine and reduce UTI 
symptoms associated with bacteriuria and pyuria (Avorn et al., 1994; Reid et al., 2001). 
Our group (LaPlante, Sarkisian, Woodmansee, Rowley, & Seeram, 2012), and others 
(Côté et al., 2011; Iswaldi et al., 2012; Lian, Maseko, Rhee, & Ng, 2012) have studied 
the antimicrobial effects of the phenolic constituents of cranberries. Some studies (Foo, 
Lu, Howell, & Vorsa, 2000a, 2000b; Gupta et al., 2012; Howell et al., 2005) have 
shown that cranberry proanthocyanidins (commonly known as PACs), with at least 
one A-type linkage, inhibit the adherence of type p-fimbriated E. coli to uroepithelial 
cells and human red blood cells. The chemistry of cranberry PACs (Lee, 2013) and 
their absorption and metabolism have been studied (Ou & Gu, 2014). However, the 
non-phenolic constituents in cranberry have been less investigated (Hotchkiss, Nunez, 
Khoo, & Strahan, 2013). Herein, we provide the first report describing the structural 
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characterization of a phenolic-free carbohydrate fraction purified from cranberry and 
its evaluation for inhibition of biofilm formation by both uropathogenic (E. coli 
CFT073) and non-pathogenic (E. coli MG1655) strains of E. coli.  
 
2. Materials and methods 
2.1. Bacterial strains and media 
E. coli strains CFT073 and MG1655 were gifts from Dr. Paul Cohen (University of 
Rhode Island).  Lysogeny Broth (LB) medium (BD, NJ, USA) was supplemented 
with 5 g/L dextrose. M63 medium (Bioworld, OH, USA) was supplemented with 1 
mM MgSO4, 2 g/L dextrose and 5 g/L casamino acid. 
 
2.2. Fractionation of cranberry materials    
2.2.1. Purification of crude cranberry hull extract (Cranf1) 
Scheme S1 (see Supplementary data) shows the fractionation flow chart of cranberry 
materials with yields and their total phenolic contents. Briefly, a pectinase (Klerzyme 
150, DSM Food Specialties, South Bend, IN, USA) degraded cranberry hull extract 
(Cranf1) was fractionated using an Agilent 971-FP flash purification system (Agilent 
Technologies, Santa Clara, CA, USA) with Biotage SNAP KP-C18-HS 120 g 
cartridges (Biotage, Charlotte, NC, USA). 50 mL of Cranf1 aqueous solution (100 
mg/mL) was loaded onto the pre-conditioned C18 column cartridge and eluted 
sequentially with 500 mL of de-ionised H2O, 500 mL of 15% methanol/water, and 
finally 500 mL of MeOH at 35 mL/min. Fractions eluted with 100% water were 
pooled as Cranf1W with a yield of 38.1% (w/w), fractions eluted with 15% methanol 
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were pooled as Cranf1b with a yield of 23.8%, and fractions eluted with 100% 
methanol were pooled as Cranf1M with a yield of 28.1% (see Scheme S1, 
Supplementary data).  
 
2.2.2. Purification of oligosaccharide enriched fraction Cranf1b 
Cranf1b was introduced onto an anion exchange column (Sepharose Q XL 16/10, GE 
Healthcare Life Sciences, Pittsburgh, PA, USA) and eluted with step-wise gradient of 
NaCl aqueous solution (0-1 M) at 5 mL/min on a ÄKTA fast protein liquid 
chromatography (FPLC) system (GE Healthcare Life Sciences). Ten mL fractions 
were collected and assayed for total carbohydrate content assay.(Masuko et al., 2005) 
The pooled carbohydrate-containing fractions were freeze-dried and desalted (10×300 
mm Bio-gel P2 column; BIO-RAD, Hercules, CA, USA). The constituents that eluted 
with 100% de-ionised H2O and 0.1 M NaCl were combined and further purified by gel 
filtration (Sephacryl S-100 HR 16/60, GE Healthcare Life Sciences; elution with 
de-ionised H2O at 0.25 mL/min), yielding two fractions designated as cranf1b-F1 and 
cranf1b-F2.  
 
2.3. Biofilm assay 
The antibiofilm property of the cranberry materials was measured against E. coli 
CFT073 and MG1655 using a modified crystal violet staining method in round bottom 
96-well microtiter plates (George, 2011; Naves et al., 2008; Niu & Gilbert, 2004). 
Bacteria colonies from TSA plates were inoculated into LB broth and incubated at 
37 °C with 175 rpm shaking for 24 h. The cultures were then diluted 100-fold in M63 
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medium, distributed in microtiter wells, and treated with a series of two-fold dilutions 
of test samples (10 - 0.019 mg/mL).  The plates were incubated at 37 ˚C for 6 h or 48 
h, gently washed with de-ionised water, and stained with 125 μL of 0.1% crystal violet 
solution for 15 min. The solution was removed and the wells were again gently 
washed with de-ionised water and dried for 1 h. 125 μL of 30% acetic acid solution 
was added to each well and incubated for 15 min. 100 μL from each well was 
transferred to a flat bottom microtiter plate and the OD550 was measured (Spectramax 
M2, Molecular devices, Sunnyvale, CA, USA). Percent biofilm formation was 
calculated as the average OD550 of three replicate treatment wells divided by average 
OD550 of replicate control wells (30 wells/plate). Each experiment was conducted in 
duplicate. 
 
2.4. High Performance Size Exclusion Chromatography (HPSEC) 
HPSEC was carried out at 40 °C on a TSKgel G3000PW column [7.5 × 300 mm 
column, Tosoh Bioscience LLC, King of Prussia, PA, USA; Hitachi LaChrom Elite 
HPLC, Tokyo, Japan; 0.6 mL/min de-ionised water, refractive index (RI) detection]. 
The molecular weights of compounds were determined by comparison of retention 
times to a standard curve (Supplementary Fig. S1) generated with standard dextrans of 
molecular weights ranging from 1,000 to 50,000 Daltons. 
 
2.5. Glycosyl composition analysis 
Sugar composition was determined by GC-MS analysis of monosaccharides (York, 
Darvill, McNeil, Stevenson, & Albersheim, 1986). Briefly, 100 μg of sample was 
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hydrolysed with 2 M TFA for 2 h at 121 °C. The hydrolyte was reduced with sodium 
borodeuteride (NaBD4) at room temperature for 1.5 h. The reduced monosaccharides 
were O-acetylated with acetic anhydride at 50 °C for 20 min. The resulting product 
was extracted with dichloromethane and analysed by GC-MS (DB-1 column, GC 
Model 6890/MS Model 5973, Agilent Technologies, Santa Clara, CA, USA). The 
monosaccharide composition was determined by comparison with a GC-MS profile of 
monosaccharide standards. 
 
2.6. Glycosyl linkage analysis 
Partially methylated acetate alditols (PMAAs) of cranf1b-F2 were analysed by 
GC-MS (Ciucanu & Kerek, 1984; York et al., 1986). Briefly, 600 μg of sample was 
permethylated with iodomethane and concentrated sodium hydroxide in DMSO. The 
permethylated oligosaccharide was hydrolysed with 2 M TFA and reduced with 
NaBD4. The sample was then acetylated with acetic anhydride and extracted with 
dichloromethane. GC-MS analysis was conducted using a Supelco SP2331 column 
(Sigma-Aldrich, St. Louis, MO, USA). The GC-MS profile was analysed by 
comparison of retention time and electron-impact fragmentation spectra with PMAA 
standards.  
 
2.7. NMR analysis 
The cranf1b-F2 was deuterium exchanged twice by D2O shake and dissolved in D2O 
with addition of 1 μL of DMSO as internal reference. 1H, 13C, 2D COSY, TOCSY, 
NOESY, HSQC and HMBC spectra were obtained on a 500 MHz NMR spectrometer 
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(Varian VNMRS 500MHz, Agilent Technologies) at 25 °C. 
 
2.8. MALDI mass spectrometry 
Cranf1b-F2 (1 mg/mL in H2O) was mixed with 2,3-dihydrobenzoic acid (DHB) matrix 
solution (v/v=1:1). Two μL of the mixture was analysed by MALDI-TOF-MS (Axima 
Performance, Shimadzu, Kyoto, Japan) in positive reflectron mode with power set at 
80kV. 500 profiles were collected for each experiment. 
 
3. Results and discussion 
In this study, we investigated a carbohydrate fraction extracted from cranberry and 
evaluated its inhibitory effect on biofilm formation of two strains of E. coli. The 1H 
NMR spectra of the original cranberry starting material (Cranf1) and its three major 
purified fractions namely, Cranf1W, Cranf1b and Cranf1M were obtained (see 
Supplementary data). The 1H NMR spectrum of Cranf1b showed only trace 
resonances above 7.0 ppm, indicating that phenolics were mostly removed by C18 
column chromatography. The crude cranberry extract cranf1b was purified by anion 
exchange chromatography and four fractions, cranf1b-F1 (64.0%), cranf1b-F2 
(17.5%), cranf1b-F3 (2.5%) and cranf1b-F4 (<1%), were collected (Figure 1a). Due to 
the limited quantities of the latter fractions, only cranf1b-F1 and cranf1b-F2 were 
further studied. Cranf1b-F1 and cranf1b-F2 were next purified by gel filtration, 
resulting in only one peak for each sample (Figure 1b).  
The homogeneity of cranf1b-F2 was further confirmed by HPSEC profile 
(Supplementary Fig. S6) and the average molecular size was predicted to be 1370 Da. 
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However, MALDI-TOF MS spectrometry of cranf1b-F2 produced a series of 
oligosaccharide sodium adduct ions (Supplementary Fig. S7), revealing it to be a 
mixture of oligomers within a close molecular weight range. The ions at 
approximately 1055, 1085, 1217, 1247, 1349, 1379, 1511, 1541 can be attributed to 
Hex3Pen4 (5 hexoses and 4 pentoses), Hex4Pen3, Hex4Pen4, Hex5Pen3, Hex4Pen5, 
Hex5Pen4, Hex5Pen5 and Hex6Pen4, respectively. Clusters of less abundant ions were 
observed above 1700 representing oligosaccharides with degrees of polymerisation 
(DP) larger than 11.  
 
 
Figure 1a. Elution profile of Cranf1b on Sepharose Q XL 16/10 column, eluted by 
stepwise gradient of NaCl (0-1 M) (total sugars, -▪-). 
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Figure 1b. Elution profile of Cranf1b-F2 on Sephacryl S-100 HR 16/60 column, 
eluted by de-ionised water (total sugars, -▪-). 
 
The GC-MS profile (Supplementary Fig. S8a) of the monosaccharide acetate alditols 
(Table 1) indicated that the cranf1b-F2 was primarily composed of arabinose (46%), 
glucose (40%), xylose (12%) and trace quantities of galactose (2%). The 
predominance of glucose, xylose and arabinose suggests that cranf1b-F2 is likely a 
xyloglucan (FRY, 1989; McNeil, Darvill, Fry, & Albersheim, 1984).  
 
Glycosyl linkages of each monosaccharide are listed in Table 1 (GC-MS profile see 
Supplementary Fig. S8b). In addition to the common glycosyl linkages known for 
xyloglucan (Fry et al., 1993) 5-α-Arab, 3-α-Arab and 3,5-α-Arab were also found in 
cranf1b-F2.  These additional linkages are consistent with arabinan side chains that 
are commonly present in cell-wall pectic substances (Caffall & Mohnen, 2009). In 
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xyloglucan nomenclature for side chain subunits (Fry et al., 1993) cranf1b-F2 glycosyl 
linkages belong to side chain subunits S, L, X and G. 1H and 13C NMR chemical shifts 
were assigned for the identified cranf1b-F2 subunits (Table 1) based on the recorded 
1D NMR and 2D NMR spectra (see Supplementary data) and in consideration of 
previous reports (Busato et al., 2005; Hoffman et al., 2005; Jia, Cash, Darvill, & York, 
2005; Shakhmatov, Toukach, Michailowa, & Makarova, 2014; Watt, Brasch, Larsen, 
& Melton, 1999).  
 
Although commonly found as separate polymer components of plant cell walls, a 
portion of xyloglucan and pectic polysaccharides are proposed to be covalently bound 
(Femenia, Rigby, Selvendran, & Waldron, 1999; Popper & Fry, 2005, 2008; 
Thompson & Fry, 2000; Vidal, Williams, Doco, Moutounet, & Pellerin, 2003). The 
putative xyloglucan-pectin complex model was first introduced by Albersheim and 
coworkers in 1973 (Keegstra, Talmadge, Bauer, & Albersheim, 1973). 
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Table 1. 13C NMR and 1H NMR chemical shifts (δ in ppm) for cranf1b-F2. 
Residue      
(Mol %) 
Subunits Linkages C1/H1 C2/H2 C3/H3 C4/H4 C5/H5 C6/H6 
Araf (56%) 
Arabinan t-α-Araf 
107.69  81.56  77.17  84.58  61.75  - 
5.14  4.13  3.95  4.03  3.84  - 
Arabinan 3,5-α-Araf 
108.11  79.83  82.90  82.11  67.14  - 
5.11  4.28  4.09  4.30  3.83/3.93 - 
Arabinan 5-α-Araf 
108.15  81.53  77.25  83.02  66.89  - 
5.08  4.12  4.02  4.21  3.88/3.79 - 
Arabinan 3-α-Araf 
107.72  80.26  84.33  83.09  - - 
5.18  4.36  3.95  4.14  - - 
S t-α-Araf 
109.87  81.66 77.05 84.44 61.81 - 
5.15  4.19 3.93 4.06 3.71 - 
Xylp (14%) 
S 2-α-Xylp 
99.20  79.47 72.47 70.03 61.87 - 
5.08  3.56 3.85 3.65 3.55 - 
L 2-α-Xylp 
98.98  81.14 - - - - 
5.14  3.6 - - - - 
X t-α-Xylp 
99.48  72.06 73.67 70.14 - - 
4.94  3.54 3.71 3.61 - - 
Galp (2%) L t-β-Galp 
105.10  - - - - - 
4.60-3.73 - - - - - 
Glcp (27%) 
_G t-β-Glclp 
105.24  - - - - - 
4.53  3.62 - - - - 
G 4,6-β-Glcp 
103.35  73.5 74.77 79.74 74.32 67.47 
4.53  3.38 3.66 3.67 3.82 3.87/3.80 
G 4,6-β-Glcp 
103.20  73.5 74.77 79.64 74.32 67.04 
4.52  3.37 3.66 3.69 3.82 3.93/3.82 
G 4-β-Glcp 
103.10  73.79 76.11 79.55 - - 
4.51  3.3 3.49 3.54 - - 
G_ α-Glcp 
92.40  71.85 - - - - 
5.21  3.57 3.82 3.64 3.94 3.86 
G_ β-Glcp 
96.34  74.44 75.32 81.15 75.41 60.52 
4.65  3.28 3.63 3.62 3.59 3.80/3.94 
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Thompson and Fry (Thompson & Fry, 2000) observed xyloglucan that co-eluted with 
anionic pectin during anion exchange chromatography and remained part of the 
complex after treatment with 8 M urea, 6 M NaOH and proteinase. Treatment with 
arabinanase and/or galactanase converted a great portion of the complex into neutral 
compounds, suggesting that covalent bonding occurs between xyloglucan and the 
Ara/Gal-rich pectic domain, likely on the arabinan and/or arabinogalactan side chains 
of a Rhamnogalacturan I region (Abdel-Massih, Baydoun, & Brett, 2003; Popper & 
Fry, 2005; Thompson & Fry, 2000). However, no NMR spectroscopic evidence for a 
covalent linkage has yet been reported. In our study, co-elution of the xyloglucan and 
arabinan components of cranf1b-F2 in every chromatography step, coupled with its 
slight acidity, (Thompson & Fry, 2000) suggests the existence of a covalent linkage.  
 
The original cranberry material (Cranf1) and its three major purified fractions, namely, 
Cranf1W, Cranf1b and Cranf1M were tested for the prevention of biofilm formation 
against E. coli MG1655, a non-uropathogenic strain, and E. coli CFT073, a 
well-studied uropathogenic strain (Welch et al., 2002) (see Table S1, Supplementary 
data). At equivalent concentrations (1.25 mg/mL), Cranf1b showed the most reduction 
in biofilm formation against the uropathogenic E. coli CFT073 strain, therefore its 
sub-fractions, Cranf1b-F1 and cranf1b-F2 were further tested against this strain. 
Although no activity was observed for cranf1b-F1, cranf1b-F2 reduced biofilm 
formation of E. coli CFT-073 by as much as 50 % at 1.25 mg/mL after 6 h of 
incubation (Figure 2a).  The reductive effect on biofilm formation was maintained for 
at least 48 h (Figure 2a) with no growth inhibition, demonstrating that the reduced 
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biofilm after 6 h is not merely due to a delay in the initiation of biofilm production. 
 
Figure 2a. Inhibition of E. coli CFT073 biofilm formation by Cranf1b-F2 at 
concentration from 0.019 mg/mL to 10 mg/mL. 
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Figure 2b. Inhibition of E. coli MG1655 biofilm formation by Cranf1b-F2 at 
concentration from 0.019 mg/mL to 10 mg/mL. 
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Interestingly, the highest inhibitory effect was not achieved at the highest 
concentration tested. While the reason for the declining prevention at higher 
concentration is not yet known, we hypothesise that aggregation of the cranf1b-F2 
sample may be partially responsible.  HPSEC analysis showed that large particles 
(>100,000 Da) formed at the higher concentration (Supplementary Fig. S6). 
Aggregation of oligosaccharides would lead to less concentration of active molecules 
in solution, hence having a potential impact on the overall activity.  Biofilm 
formation by E. coli MG1655 was also sensitive to the effects of cranf1b-F2 (Figure 
2b), but not to cranf1b-F1. A concentration-dependent reduction in biofilm formation 
was observed between 10 and 0.625 mg/mL; however, an increase in biofilm 
formation was consistently observed between 0.625 and 0.156 mg/mL of cranf1b-F2. 
The distinct dose-response patterns between CFT073 and MG1655 may derive from 
their different abilities to form and sustain biofilms. MG1655 naturally produces much 
lighter biofilm than CFT073, which likely makes it more vulnerable to biofilm 
modifying agents.  
  
As previously discussed, the role of the polyphenols (including PACs) present in 
cranberries in its preventive effects against urinary tract infections has been 
extensively studied by several groups (LaPlante, Sarkisian, Woodmansee, Rowley, & 
Seeram, 2012; Gupta et al., 2012; Howell et al., 2005). Thus, it is possible that the 
multiple constituents, including polyphenols and oligosaccharides, present in the 
cranberry whole fruit act additively, complementarily, and/or synergistically in its 
overall biological effects. Interestingly, in the current study, we did not observe any 
  
 
 
16 
growth inhibitory and anti-biofilm effects of the Cranf1M fraction (which was 
enriched in polyphenol constituents) on both of the E. coli strains which was in 
agreement with our previous report (LaPlante, Sarkisian, Woodmansee, Rowley, & 
Seeram, 2012). Therefore, while it appears that the phenolic constituents did not 
contribute to the inhibition of biofilm formation by the uropathogenic E. coli CFT073 
strain (based on our bioassays), their overall contribution to the prevention of urinary 
tract infections by the whole cranberry fruit should not be discounted.   
  
4. Conclusion 
In conclusion, our study demonstrates that a phenolic-free, oligosaccharide component 
of cranberry modifies the biofilm formation of E. coli strains CFT073 and MG1655. 
Thus, in addition to PACs and other polyphenols, certain carbohydrate components in 
cranberry may also contribute to its overall anti-infective properties.  Further 
investigation to clarify the structure-activity relationships of these oligosaccharides is 
currently being pursued by our group. 
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Scheme S1 
 
 
 
 
Scheme S1. Fractionation flow chart of cranberry materials with yields and 
their total phenolic contents. 
*Total phenolic contents were measured by the Folin-Ciocalteau method. 
Sample Total phenolic content (mg/100 g of gallic acid equivalents)* 
Cranf1 5173 ± 12 
Cranf1W 180 ± 4 
Cranf1b 3833 ± 88 
Cranf1M 15706 ± 457 
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Figure S1 
 
Figure S1. Standard curve of dextrans (MW 1000 to 50000 Da) on TSKgel 
G3000PW column. 
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Figure S2 
 
Figure S2. 1H NMR of Cranf1. 
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Figure S3 
 
Figure S3. 1H NMR of Cranf1W. 
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Figure S4 
 
Figure S4. 1H NMR of Cranf1b. 
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Figure S5 
 
Figure S5. 1H NMR of Cranf1M. 
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Figure S6 
 
Figure S6. Normalized HPSEC profiles of 10 mg/mL (blue) and 50 mg/mL (red) 
of Cranf1b-F2. 
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Figure S7 
 
Figure S7. MALDI-TOF-MS spectrum of Cranf1b-F2. 
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Figure S8 
Figure S8a. GC-MS profile of Cranf1b-F2 glycosyl composition analysis. 
 
 
Figure S8b. GC-MS profile of Cranf1b-F2 glycosyl linkage analysis. 
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Figure S9 
 
Figure S9. 1H NMR of Cranf1b-F2. 
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Figure S10 
 
Figure S10. 13C NMR of Cranf1b-F2. 
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Figure S11 
 
Figure S11. gCOSY NMR of Cranf1b-F2. 
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Figure S12 
 
Figure S12. zTOCSY NMR of Cranf1b-F2. 
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Figure S13 
 
Figure S13. gHSQC NMR of Cranf1b-F2. 
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Figure S14 
 
Figure S14. gHMBC NMR of Cranf1b-F2. 
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Figure S15 
 
Figure S15. NOESY NMR of Cranf1b-F2. 
  
 
 
42 
Table S1 
 E. Coli CFT073 E. Coli MG1655 
Cranf1 N.R.*. N.R. 
Cranf1W 9.1% 49.7% 
Cranf1b 12.6% 43.4% 
Cranf1M N.R. N.R. 
Table S1. Percentage reduction in biofilm formation of E. coli strains CFT073 
and MG1655 by Cranf1, Cranf1W, Cranf1b and Cranf1M at 1.25 mg/mL. 
*N.R.: No observable reduction in biofilm formation. 
 
Sample 
Strai
n 
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ABSTRACT 
BACKGROUND: The formation and accumulation of advanced glycation 
end-products (AGEs) are implicated in several chronic human illnesses including 
type-2 diabetes, renal failure, and neurodegenerative diseases.  The cranberry 
(Vaccinium macrocarpon) fruit has been previously reported to show anti-AGEs 
effects, attributed primarily to its phenolic constituents. However, there is lack of 
similar data on the non-phenolic constituents found in the cranberry fruit, in 
particular, its carbohydrate constituents. Herein, a chemically characterized 
oligosaccharide-enriched fraction purified from the cranberry fruit was evaluated for 
its potential anti-AGEs and free radical scavenging effects.   
OBJECTIVE: The aim of this study was to evaluate the in vitro anti-AGEs and free 
radical scavenging effects of a chemically characterized oligosaccharide-enriched 
fraction purified from the North American cranberry (Vaccinium macrocarpon) fruit. 
METHOD: The cranberry oligosaccharide-enriched fraction was purified from 
cranberry hull powder and characterized based on spectroscopic and spectrometric 
(NMR, MALDI-TOF-MS, and HPAEC-PAD) data. The oligosaccharide-enriched 
fraction was evaluated for its anti-AGEs and free radical scavenging effects by the 
bovine serum albumin-fructose, and DPPH assays, respectively.  
RESULTS: Fractionation of cranberry hull material yielded an 
oligosaccharide-enriched fraction named Cranf1b-CL. The 1H NMR and 
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MALDI-TOF-MS revealed that Cranf1b-CL consists of oligosaccharides ranging 
primarily from 6-mers to 9-mers. The monosaccharide composition of Cranf1b-CL 
was arabinose (25%), galactose (5%), glucose (47%) and xylose (23%). In the 
bovine serum albumin-fructose assay, Cranf1b-CL inhibited AGEs formation in a 
concentration-dependent manner with comparable activity to the synthetic 
antiglycating agent, aminoguanidine, used as the positive control (57 vs. 75%; both 
at 500 µg/mL). In the DPPH free radical scavenging assay, Cranf1b-CL showed 
superior activity to the synthetic commercial antioxidant, butylated hydroxytoluene, 
used as the positive control (IC50 = 680 vs. 2200 µg/mL, respectively). 
CONCLUSION: The in vitro anti-AGEs and free radical scavenging effects of 
cranberry oligosaccharides support previous data suggesting that these constituents 
may also contribute to biological effects of the whole fruit beyond its phenolic 
constituents alone. Also, this is the first study to evaluate a chemically characterized 
oligosaccharide fraction purified from the North American cranberry fruit for 
anti-AGEs and free radical scavenging properties.    
 
Keywords: Vaccinium macrocarpon, cranberry, oligosaccharides, advanced 
glycation end-products, free radical scavenging  
  
 
 
46 
1. Introduction 
The North American cranberry (Vaccinium macrocarpon Aiton) is widely consumed 
worldwide, both as a fruit and as processed products such as juice, sauces, and 
extracts. The cranberry fruit is a rich source of phytochemicals [1], in particular 
phenolic compounds belonging to the sub-classes flavonoids [2, 3], and 
proanthocyanidins (PACs) [4]. Moreover, phenolic-enriched cranberry extracts, and 
singly purified cranberry phenolic constituents have been extensively studied for a 
vast array of biological activities including antioxidant, antimicrobial, 
anti-inflammatory, anticancer, and anti-diabetic effects [5]. While the majority of 
these biological studies have focused on cranberry’s phenolic constituents, emerging 
data, including recent studies from our group and others [6, 7], suggest that the 
non-phenolic constituents, especially oligosaccharides, may also play a role in its 
health benefits.    
Glycation occurs spontaneously both in vitro and in vivo wherein protein side 
chains non-enzymatically react with carbohydrates to form glycation adducts, 
referred to as advanced glycation end-products (AGEs). The gradual accumulation 
of AGEs in vivo has been implicated in the pathology of many chronic diseases 
including diabetic complications and neurodegenerative disorders [8, 9]. The 
build-up of AGEs is deleterious for two reasons. First, AGEs bind specifically to 
proteins including the receptor for AGEs (known as RAGE) which upregulates 
oxidative stress and inflammation [8] and is implicated in several diseases. Second, 
AGEs can enhance the crosslinking of extracellular proteins, resulting in a loss of 
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functions [10]. Therefore, the reduction of AGE formation using synthetic 
pharmaceutical agents, such as aminoguanidine (AG), has been investigated in 
clinical studies [11]. Given the undesirable side effects of several synthetic agents, 
including AG [11], the utilization of natural products as dietary intervention 
strategies for the prevention and therapy of AGE-related diseases holds great 
promise [12].  
While cranberry and its derived products have been extensively studied for a 
wide range of biological properties, to date, there is limited data on the effects of 
cranberry fruit constituents on the formation of AGEs [13, 14].  In these studies, a 
purified phenolic-enriched fraction, high in PAC content, was shown to inhibit 
protein glycation by scavenging reactive carbonyl species. However, the authors also 
reported that phenolic-free water fractions, purified from the cranberry fruit, also 
exerted antiglycative effects but the active constituents present therein were not 
identified [13, 14]. 
Our group has recently reported on the chemical characterization and 
antimicrobial effects of an oligosaccharide-enriched fraction purified from a 
water-methanol fraction of cranberry [6]. Therefore, we hypothesized that these 
oligosaccharide constituents could impart anti-AGEs effects to the fruit beyond its 
phenolic constituents alone. In light of the aforementioned points, and given our 
group’s ongoing research interest in identifying natural products with antiglycating 
activities [15-17], the current study was designed to evaluate the inhibitory effects of 
cranberry oligosaccharides against the formation of AGEs.  
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Herein, an oligosaccharide-enriched fraction (named Cranf1b-CL), purified 
from pectinase treated whole cranberry fruit material, was evaluated for its 
anti-AGEs and free radical scavenging effects in vitro. Bovine serum albumin (BSA) 
and D-fructose were used as the model protein and glycating agent, respectively, for 
the AGEs assay. Inhibition of AGEs formation by Cranf1b-CL was comparable to 
AG at equivalent concentrations. Cranf1b-CL was also found to have free radical 
scavenging activity superior to the synthetic antioxidant, butylated hydroxytoluene 
(BHT) when evaluated in the DPPH assay. 
 
2. Methods 
2.1. Chemicals 
Bovine serum albumin (BSA), D-fructose, 2,5-dihydroxy benzoic acid (2,5-DHB), 
trifluoroacetic acid (TFA), methylglyoxal (MGO), 1,2-phenylenediamine (PD),  
2,3-dimethylquinoxaline (DQ), 2,2-diphenyl-1-picrylhydrazyl (DPPH), and 
aminoguanidine hydrochloride (AG) were purchased from Sigma-Aldrich Chemical 
Co. (St. Louis, MO, USA). All solvents used were HPLC grade and purchased from 
Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). 
 
2.2. Fractionation of Cranberry Material 
Pectinase (Klerzyme 150, DSM Food Specialties, South Bend, IN, USA) treated 
cranberry hull powder was generously provided by Ocean Spray Cranberries, Inc. 
(Middleboro, MA, USA) and further fractionated as previously reported [6] with  
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modification (shown in Scheme 1) using a CombiFlash Rf purification system 
(Teledyne ISCO, Inc., Lincoln, NE, USA). Briefly, 20 mL of an aqueous solution of 
the pectinase treated cranberry powder (100 mg/mL) was injected onto a RediSep 
GOLD C18 Reverse-phase column (Teledyne ISCO, Inc., Lincoln, NE, USA) and 
eluted sequentially with 500 mL of de-ionized water, 500 mL of 15% 
methanol/water, and 500 mL of 100% methanol. Eluates from each gradient system 
were individually pooled and freeze-dried. Three major fractions, Cranf1W (761 mg, 
38.1%) eluted with 100% de-ionized water, Cranf1b (476 mg, 23.8%) eluted with 
15% methanol/water, and Cranf1M (562 mg, 28.1%) eluted with 100% methanol 
were obtained. 
The oligosaccharide constituents of Cran1b were purified using a Hypersep 
Hypercarbon solid phase extraction (SPE) cartridge (1 gram, Thermo Scientific, 
Waltham, MA, USA). The SPE cartridge was first conditioned by eluting with 6 mL 
of acetonitrile/H2O (50%, v/v) and then washed three times with 6 mL of deionized  
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Scheme 1. Fractionation and purification of cranberry materials. 
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H2O. Two mL of an aqueous solution of Cran1b (5 mg/mL) was slowly eluted 
through the cartridge and washed three times with 6 mL of deionized water. The 
oligosaccharide-enriched fraction was then eluted with 6 mL of acetonitrile/ H2O 
(30%) acidified with 0.1% trifluoroacetic acid (TFA). The resulting fraction was 
then finally purified using a C18 reverse-phase SPE cartridge (50 mg, Fisher 
Scientific, Waltham, MA, USA), by eluting with deionized H2O, and dried in vacuo 
to yield Cranf1b-CL (7.5 mg). 
 
2.3. Nuclear Magnetic Resonance (NMR) Spectroscopy  
Five mg of Cranf1b-CL was dissolved in 0.5 mL D2O (99.99%, Sigma-Aldrich, St. 
Louis, MO, USA) and transferred to a 5 mm NMR tube. 1H NMR spectra was 
recorded at 25 °C on a Bruker 300 MHz spectrometer (Billerica, MA, USA).   
 
2.4. Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) 
Mass Spectrometry (MS)  
The molecular sizes of oligosaccharides in Cranf1b-CL were recorded by 
MALDI-TOF-MS (Axima Performance, Shimadzu, Kyoto, Japan) as previously 
reported using 2,5-dihydroxy benzoic acid (2,5-DHB) as the matrix [18]. Briefly, 
2,5-DHB matrix solution was prepared as 50% acetonitrile/H2O solution at 10 
mg/mL. Two μL of Cranf1b-CL aqueous solution (5 mg/mL) was mixed well with 2 
μL of the matrix solution then 2 μL of the mixture was spotted onto a MALDI plate, 
air dried, and analyzed in positive reflectron mode with the power set at 80 kV.  
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2.5. Monosaccharide Composition Analyses 
Cranf1b-CL (200 μg) was hydrolyzed with 200 μL of 2M TFA in an ampoule for 2 h 
at 120 °C. The hydrolyte was dried under a stream of nitrogen. The residual acid was 
removed by adding 200 μL of isopropanol and dried in vacuo. The monosaccharide 
composition of Cranf1b-CL hydrolyte was analyzed by High Performance Anion 
Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) [19] 
using a Hamilton RCX-30 250/4.6 column (Metrohm AG, Riverview, FL, USA) on a 
940 Professional IC Vario system (Metrohm AG, Riverview, FL, USA) and eluted 
with isocratic 16 mM NaOH at 1 mL/min. Fucose, arabinose, rhamnose, galactose, 
glucose, xylose and fructose were used as monosaccharide standards. Unhydrolyzed 
aqueous solution of Cranf1b-CL was prepared (1 mg/mL) and its monosaccharide 
content was quantitatively analyzed by HPAEC-PAD eluting with 100 mM NaOH at 
1 mL/min.  
 
2.6. DPPH Free Radical Scavenging Assay 
The free radical scavenging capacity of Cranf1b-CL was evaluated by the 
2,2-diphenyl-1-picrylhydrazyl (DPPH) assay based on our previously reported 
method [20]. Briefly, 100 μL of test samples and 100 μL of a 0.20 mM DPPH in 
50% aqueous methanol solution were mixed for 30 min at room temperature. The 
absorbance was read at 517 nm using a micro-plate reader (SpectraMax M2, 
Molecular Devices Corp., Sunnyvale, CA, USA). The scavenging capacity of the 
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sample was calculated as follows: [(ΔAcontrol − ΔAsample)/ΔAcontrol] × 100%. 
 
2.7. Advanced Glycation End-Products (AGEs) Assay 
The inhibitory effects of Cranf1b-CL of the formation of advanced glycation 
end-products (AGEs) was evaluated by the BSA-fructose assay wherein bovine 
serum albumin (BSA; 10 mg/mL) and D-fructose (100 mM) were used as the model 
protein and glycating agent, respectively as previously reported [17]. Treatments 
included varying concentrations of Cranf1b-CL ranging from 20 to 500 µg/mL and a 
synthetic anti-AGEs agent, aminoguanidine (AG), at equivalent concentrations, 
which served as the positive control.  Each sample was then incubated in the dark 
at 37 °C for 60 h and their intrinsic fluorescence was measured using a Spectra Max 
M2 spectrometer (Molecular Devices, Sunnyvale, CA, USA) at an excitation 
wavelength of 340 nm and an emission wavelength of 435 nm. Statistical analysis 
was conducted using one-way factorial ANOVA with Tukey-Kramer post hoc 
comparisons. All results were expressed as means ± SD (n = 3) with significance (*) 
defined as p≤0.05. 
 
2.8. Methylglyoxal (MGO) Trapping Assays 
Cranf1b-CL was evaluated for methylglyoxal (MGO) trapping capacity based on our 
previously reported method [17].  A reaction solution consisting of MGO (5 mM), 
PD (derivatization reagent, 20 mM), and DQ (internal standard, 5 mM) were freshly 
prepared in 0.1 M phosphate buffer, pH 7.4. Cranf1b-CL (0.25 mL of 1000 µg/mL) 
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was added to MGO (0.25 mL of 5 mM). After incubating at 37 °C for 1 h, 0.125 mL 
of PD and DQ were each added to mixture. The reaction was kept at room 
temperature for 30 min. The amount of derivative of residual MGO 
(2-methylquinoxaline, 2-MQ) was quantified by HPLC-DAD. The percentage 
decrease of MGO was calculated using the following equation: % MGO decrease = [1 
- (MGO amounts in solution with tested sample/MGO amounts in control solution)] x 
100%. 
 
3. Results  
3.1. Purification of Cranberry Oligosaccharides 
Pectinase treatment is a common process in cranberry juice production and is used 
to help extract, clarify, and modify the juice [21]. Therefore, starting from an 
pectinase enzyme treated cranberry powder, an oligosaccharide-enriched fraction, 
Cranf1b (23.8%; the 15% methanol:H2O eluate) was obtained from C18 reverse 
phase flash chromatography (Scheme 1). The oligosaccharides of Cranf1b were 
further purified by porous graphitized carbon solid phase extraction (SPE) and C18 
SPE to remove the residual monosaccharides, salts, and other trace contaminants 
(proteins, lipids, and pigments). The 1H NMR spectrum (Figure 1) of Cranf1b-CL 
showed proton resonances between 3.0 ppm and 4.5 ppm, and a group of resonances 
between 4.5 ppm and 5.3 ppm that are consistent with characteristic signals for 
anomeric protons in carbohydrates. Notably, there are no visible aromatic protons 
between 6.5 ppm and 8.0 ppm in the 1H NMR spectrum of Cranf1b-CL indicating 
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that no phenolic components are present in this fraction. This confirmed that 
Cranf1b-CL was a “phenolic-free” and “oligosaccharide-enriched” fraction purified 
from cranberry fruit. 
 
3.2. Analysis of Cranberry Oligosaccharides by MALDI-TOF Mass 
Spectrometry 
MALDI-TOF mass spectrometry (Figure 2) of Cranf1b-CL revealed several 
oligosaccharide sodium adduct ions [M+Na]+ that were composed of hexoses (Hex) 
and pentoses (Pen). Major adduct ions at m/z 923, 953, 1055, 1085, 1217, 1247 and 
1379 were consistent with oligosaccharides with compositions of Hex3Pen3, 
Hex4Pen2, Hex3Pen4, Hex4Pen3, Hex4Pen4, Hex5Pen3 and Hex5Pen4, respectively. 
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Figure 1. 1H NMR spectrum (300 MHz, D2O) of Cranf1b-CL. 
 
 
No aromatic 
protons 
Carbohydrate 
anomeric protons 
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Figure 2. MALDI-TOF-MS of Cranf1b-CL. H3P3: [Hexose3Pentose3+Na]+, m/z 
923; H4P2: [Hexose4Pentose2+Na]+, m/z 953; H3P4: [Hexose3Pentose4+Na]+, m/z 
1055; H4P3: [Hexose4Pentose3+Na]+, m/z 1085; H4P4: [Hexose4Pentose4+Na]+, 
m/z 1217; H5P3: [Hexose5Pentose3+Na]+, m/z 1247; H5P4: 
[Hexose5Pentose4+Na]+, m/z 1379. 
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3.3. Monosaccharide Composition Analysis of Cranberry Oligosaccharides by 
HPAEC-PAD  
The HPAEC-PAD chromatogram (Figure 3) of hydrolyzed Cranf1b-CL 
indicated that Cranf1b-CL was composed of four major monosaccharides arabinose 
(25%), galactose (5%), glucose (47%) and xylose (23%). The monosaccharide 
content of unhydrolyzed Cranf1b-CL was also evaluated by HPAEC-PAD (Figure 4) 
which showed only a trace amount (0.7%) of glucose present in Cranf1b-CL and no 
other measurable levels of monosaccharides (Figure 4). 
 
3.4. Free Radical Scavenging Activity of Cranberry Oligosaccharides  
As shown in Figure 5, Cranf1b-CL showed free radical scavenging capacity in 
a concentration-dependent manner. At concentrations ranging from 1250 – 5000 
μg/mL, the oligosaccharides scavenged more than 50% of free radicals (59 - 84%, 
respectively). Also, Cranf1b-CL had an IC50 value of 680 μg/mL, superior to the 
positive control, butylated hydroxytoulene (BHT), a synthetic commercial 
antioxidant, which had an IC50 value of 2200 μg/mL. Notably, Cranf1b-CL (at 1000 
μg/mL) did not show any methylglyoxal (MGO) trapping capacity (data not shown). 
 
3.5. Anti-AGEs activity of Cranberry Oligosaccharides   
For the anti-AGEs assay (Figure 6), the glycation levels of a BSA-fructose 
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Figure 3. HPAEC-PAD chromatogram of monosaccharide components in 
hydrolyzed Cranf1b-CL. 
  
 
 
60 
 
 
Figure 4. HPAEC-PAD chromatogram of monosaccharide components present 
in unhydrolyzed Cranf1b-CL. 
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Figure 5. Cranf1b-CL showed free radical scavenging activity in the DPPH assay. 
Each experiment was conducted in triplicate and all data were expressed in 
mean ± SD (n=3). BHT (butylated hydroxytoluene) served as the positive 
control.  
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Figure 6. Advanced glycation end-product (AGEs) levels as characterized by 
intrinsic fluorescence (FU) in BSA-fructose solutions. Each experiment was 
conducted in triplicate and all data were expressed in mean ± SD (n=3) with 
significance (*) defined as p≤0.05. Aminoguanidine, a synthetic antiglycating 
agent, served as the positive control. 
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solution (negative control), or BSA-fructose solutions co-treated with Cranf1b-CL 
(treatment) or with AG (positive control) were evaluated. After an incubation period 
of 60 h, all of the BSA-fructose solutions generated fluorescence detectable at 340 
nm/435 nm confirming the formation of AGEs. However, solutions treated with 
Cranf1b-CL and AG yielded fluorescence significantly lower than that of negative 
control (p ≤ 0.05). Among the Cranf1b-CL treated samples, the highest inhibitory 
effects were observed at 200 and 500 µg/mL with reduction in AGEs formation by 
53.3% and 56.8%, respectively. At equivalent concentrations, the inhibitory levels of 
AG were comparable to Cranf1b-CL with reduction in AGEs formation by 73.1% 
and 75.2%, respectively. However, at concentrations equal to or lower than 100 
µg/mL, Cranf1b-CL showed comparable or more potent anti-AGEs activities than 
AG. For example, at 50 µg/mL, Cranf1b-CL reduced AGEs formation by 34.8% 
while AG reduced AGEs formation by 28.8% at an equivalent concentration of 50 
µg/mL.   
 
4. DISCUSSION 
Oligosaccharides show numerous biological activities including antioxidant [22, 
23], anti-inflammatory [24], and immuno-stimulating effects [25] but those purified 
from cranberry have only been previously evaluated for antimicrobial properties [6, 
7].  Therefore, in the current study, purified cranberry oiligosaccharides, namely, 
Cranf1b-CL, was tested for its in vitro antiglycative and free radical scavenging 
effects.  
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Overall, Cranf1b-CL inhibited the formation of AGEs in a 
concentration-dependent manner which is likely to be related to its oligosaccharide 
content.  Notably, it has been reported that the antiglycating effects of the 
polyphenolic constituents, namely PACs, in cranberries are mediated by their 
reactive carbonyl species scavenging capacity [13]. In the current study, we 
evaluated the ability of Cranf1b-CL to trap the reactive carbonyl species, 
methylglyoxal (MGO), using methods previously reported by our group [17]. 
Interestingly, Cranf1b-CL did not show any MGO scavenging capacity suggesting 
that its mechanisms of antiglycative effects are different from the polyphenolic 
constituents of cranberries. Previous studies have shown that oligosaccharides 
purified from wheat bran show antiglycating effects mediated through metal 
chelating activities [26].  Therefore, further studies are warranted to evaluate the 
mechanisms of antiglycating activities of oligosaccharides purified from cranberry. 
The limitations of our current study are common to in vitro studies which do not 
account for physiological relevant considerations such as bioavailability and 
metabolism. While there is limited data on the bioavailability and metabolism of 
oligosaccharides, recent studies have underscored the role of intestinal microbiota in 
their biotransformation [27-29]. Given the relatively large size of these molecules, it 
is unlikely that they would be absorbed directly as their intact forms. Thus, whether 
these compounds would be present in tissues in their bioactive (intact and/or 
metabolized) forms to exert potential anti-AGEs effects would require further in vivo 
studies.  Nevertheless, the current study provides initial data to support the 
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anti-AGEs and free radical scavenging potential of oligosaccharides purified from 
the North American cranberry fruit. 
 
5. CONCLUSION 
In summary, a chemically characterized oligosaccharide-enriched fraction 
purified from cranberry fruit was shown to exert anti-AGEs and free radical 
scavenging effects. The current study adds to emerging data supporting the 
biological effects of cranberry oligosaccharides suggesting that these constituents 
may impart potential health benefits to the whole cranberry fruit beyond its phenolic 
constituents alone. Also, this is the first study to evaluate a chemically characterized 
oligosaccharide fraction purified from the North American cranberry fruit for 
anti-AGEs and free radical scavenging properties.    
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Abstract 
Chronic Pseudomonas aeruginosa infections are often associated with biofilm 
formation that protects the bacteria from antibiotic treatment and host immune 
defense. Previously, ginseng aqueous extract were shown to significantly inhibit the 
biofilm formation by P. aeruginosa. One of the key factor in controlling the biofilm 
formation and dispersal is a secondary messenger molecule cyclic di-GMP. 
Biofilm-associated bacterial physiologies are closely regulated by the intracellular 
cyclic di-GMP level, therefore molecules that decrease intracellular cyclic di-GMP 
level would potentially prevent biofilm formation or cause mature biofilm dispersal. 
In the present study, activity-directed fractionation of ginseng polysaccharides 
identified an acidic pectic polysaccharide CGP-6-f2 that exhibited a 
concentration-dependent reduction of the intracellular cyclic di-GMP level to as low 
as 30% at 5 mg/mL. In addition, intraperitoneal injection of CGP-6-f2 in mice 
successfully dispersed pre-formed biofilm on a silicon implant within 24 h. Our 
study suggests that ginseng pectic polysaccharide may help disrupt P. aeruginosa 
biofilm and treat biofilm associated chronic infections. 
 
Keywords: Pseudomonas aeruginosa, biofilm, ginseng, cyclic di-GMP, pectic 
polysaccharide
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1. Introduction 
Pseudomonas aeruginosa is a common Gram-negative, opportunistic human 
pathogen that causes varieties of chronic infections with significant morbidity and 
mortality rates especially in immune-compromised patients.1,2 P. aeruginosa is the 
leading pathogenic bacterium associated with the chronic lung infection in cystic 
fibrosis (CF) patients. It develops thick biofilm in the respiratory tract, which may 
ultimately lead to lung failure. Furthermore, P. aeruginosa infections account for 
10%-15% of nosocomial infections worldwide, which are often associated with 
medical devices and include eye infections by contact lenses, urinary tract infections 
by urinal catheter, and pneumonia by mechanic ventilator.3 Together with innate 
high resistance to a great number of antibiotics,4 biofilm associated P. aeruginosa 
chronic infection is the foremost factor responsible for repeated hospitalizations, 
declined organ functions and early mortality of infected patients.   
 
Biofilm is an aggregation of bacterial cells embedded in a polymeric matrix 
consisting of polysaccharides, proteins and DNA.5,6 In fact, biofilm is the 
predominant living style for most bacteria and is associated with over 80 percent of 
microbial infections.7 Living in biofilm as a multicellular community provides not 
only significant protection to the bacterial cells from environmental stresses, such as 
host immune defense system or antibiotic treatment (up to 1,000-fold more resistant), 
but also an ideal platform for exchanging genes that would benefit the bacterial 
community, thus facilitating the emergence and spread of drug resistance.8 Because 
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of the development of biofilm formation, pathogens associated with chronic 
infections are remarkably difficult to eradicate with traditional antibiotics, causing 
huge global economic burden. In fact, it is estimated that 17 million people in 
United States are suffering biofilm related chronic infections.9 During the past three 
decades, only a few new antibiotics have reached the market while multi-drug 
resistant strains of human pathogens are emerging at a much faster rate.10,11 Thus, 
rather than new molecules in the same traditional antimicrobial categories, 
therapeutics with novel mechanisms of action are in urgent need. Drugs that prevent 
or eradicate existing biofilm infections are especially important. Such drugs would 
not necessarily involve bactericidal effect, hence lowering the possibility of 
establishing drug resistance.  
 
The secondary messenger molecule cyclic dimeric guanosine monophosphate 
(c-di-GMP) has numerous effects on P. aeruginosa physiology (see Figure 1). 
Studies have shown that c-di-GMP plays an essential role in regulating the formation 
and dispersal of biofilm.7,12,13 Intracellular level of c-di-GMP is dynamically 
synthesized from two guanisine-5’-triphosphates (GTPs) by diguanylyl cyclases 
(DGCs) and is degraded into 5’-phosphoguanylyl-(3’->5’)-guanosine phosphate 
(pGpG) by phosphodiesterases (PDEs). DGCs and PDEs are often associated with 
sensor domains that are stimulated by environmental input signals such as quorum 
sensing molecules, oxygen level, nitric oxide level, temperature and chemical 
stresses. Environmental input signals induce fluctuations of intracellular level of 
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c-di-GMP that are then sensed by a group of c-di-GMP binding proteins (effectors) 
or RNA aptamers. These effectors or RNA aptamers will directly or indirectly effect 
immediate downstream cellular transcriptional, translational or post-translational 
functions. For P. aeruginosa, these c-di-GMP binding receptors include PilZ that 
downregulates fimbriae involved twitching motility; Alg44 and PelD that upregulate 
the production of extracellular polysaccharide alginate and pel, which are primary 
components for P. aeruginosa biofilm matrix; and FleQ that downregulates the 
synthesis of flagella and upregulates the pel production. Therefore, modulating 
intracellular levels of c-di-GMP could represent a new target for shifting the 
bacterial living state from sessile to mobile. 
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Figure 1. Cyclic di-GMP and regulation of biofilm dispersal 
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Panax ginseng C.A. Meyer has been traditionally used as an herbal medicine in the 
East Asia, which is believed to strengthen immune system and boost energy. 
Because ginseng is often prepared by boiling in hot water, water-soluble components 
from ginseng have been extensively investigated. As one of the major water-soluble 
components, ginseng polysaccharides have been reported as having 
immunostimulating,14 anti-tumor,15 anti-oxidant, 16 anti-adhesive17 and 
antirotavirus18 properties. Previously, ginseng hot water extract has been reported to 
prevent P. aeruginosa biofilm formation as well as to disperse mature biofilm 
without having bactericidal effects. In the present study, we identified and 
characterized a pectic polysaccharide CGP-6-f2 that inhibits the cyclic di-GMP 
production in P. aeruginosa and exhibits in vivo biofilm dispersing effect. 
 
2. Materials and methods 
2.1. Materials and chemicals 
The ginseng (Panax ginseng C.A. Meyer) root powder (ginseng age: 5-6 years, Jilin, 
China) was kindly provided by University of Copenhagen (Copenhagen, Denmark). 
The Q Sepharose, Sepharose CL-6B, Sephadex G-25 resins were purchased from 
GE Healthcare Life Sciences (Pittsburgh, PA, USA). All other chemicals were of 
analytical grade and purchased from Sigma-Aldrich (St. Louis, MO, USA) unless 
otherwise specified. 
2.2. Bacterial culture 
P. aeruginosa strains were inoculated on ABTG (2g/L (NH4)2SO4, 6g/L Na2HPO4, 3 
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g/L KH2PO4, 3g/L NaCl, 11 mg/L CaCl2, 95 mg/L MgCl2, 0.5 mg/L FeCl3, 2.5 mg/L 
thiamine, 5 g/L glucose) agar plate supplemented with gentamicin (60 mg/L). For 
measurement of intracellular c-di-GMP level, P. aeruginosa strains were cultured in 
ABTG supplemented with casamino acids (5 g/L) and gentamicin (60 mg/L). For in 
vivo biofilm dispersal study, P. aeruginosa strains were cultured in Lysogeny Broth 
(LB) medium. 
 
2.3. General methods 
Total carbohydrate content was determined by phenol-sulfuric acid method19, using 
glucose as a standard. Uronic acid content was determined by m-hydroxydiphenyl 
method20 using galacturonic acid as a standard. Ion exchange and gel permeation 
chromatographies were performed on a Fast Protein Liquid Chromatography (FPLC) 
system (GE Healthcare Life Sciences) and detected by total carbohydrate and uronic 
acid content assays. 
 
2.4. Extraction 
Raw ginseng powder was washed with 95% ethanol three times and then dissolved 
in distilled water. With the addition of 95% ethanol (4 volumes), the crude 
polysaccharide was precipitated overnight at 4 °C. After centrifugation, the 
precipitate was re-dissolved in distilled water and treated with 1/4 volume of Sevag 
reagent21 (4:1 Chloroform: n-Butanol, v/v) to remove any remaining protein. After 
centrifugation, the water layer was dialyzed (MWCO 12,000-14,000 Da, Spectrum 
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Laboratories, Inc., Rancho Dominguez, CA, USA) against distilled water with 
stirring for 48 h. The retained materials were dried by lyophilization to yield a 
de-proteined crude ginseng polysaccharide (CGP). The extraction and fractionation 
of ginseng polysaccharide are described in Figure 2. 
 
Figure 2. Ginseng polysaccharide extraction and purification flow chart. 
 
2.5. Polysaccharide purification 
2.5.1 Anion exchange chromatography on Q Sepharose 
CGP (1 gram) was dissolved in 50 mL of distilled water and loaded onto a 
semi-preparative anion exchange column (Hiprep Q XL 16×100 mm, GE Healthcare 
Life Sciences) connected to the FPLC system. The column was pre-equilibrated with 
distilled water and eluted by an increasing step-wise gradient of sodium chloride (0 
to 1 M) at 5 mL/min for 300 min (see Figure 3). The fractions were collected every 
15 mL and pooled based on total carbohydrate and uronic acid content assays. The 
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pooled fractions were then reduced in volume by lyophilization and subjected to a 
G-25 desalting column (Hiprep desalting 26×100 mm, GE Healthcare Life Sciences). 
The desalting process was monitored using a conductivity detector and total 
carbohydrate content assay. The salt free fractions were then freeze-dried to obtain 
seven fractions, CGP-1 (32.1 mg), CGP-2 (32.2 mg), CGP-4 (42.3 mg), CGP-5 
(73.2 mg), CGP-6 (57.8 mg) and CGP-7 (46.2 mg).  
 
 
Figure 3. The elution profile of CGP on Q Sepharose XL column. 
 
2.5.2 Gel permeation chromatography on Sepharose CL-6B 
CGP-6 (100mg) was dissolved in 10 mL of distilled water and applied to a 
semi-preparative Sepharose CL-6B gel permeation column (16×400 mm, GE 
Healthcare Life Sciences) and eluted with 0.15 M NaCl at 0.5 mL/min for 500 min 
(see Figure 4). The eluate was collected every 5 mL and pooled based on the total 
carbohydrate and uronic acid assays. The pooled fractions of interest were desalted 
as described above and then lyophilized to obtain two major fractions, CGP-6-f1 
  
 
 
80 
(7.9 mg) and CGP-6-f2 (70.4 mg). 
 
 
Figure 4. The elution profile of CGP-6 on Sepharose CL-6B column 
 
2.6. High performance size-exclusion chromatography 
A 1 mg/mL CGP-6-f2 solution was prepared and high performance size-exclusion 
chromatography was carried out by Complex Carbohydrate Research Center (CCRC, 
University of Georgia, Athens, GA) using a Superose 12 column (GE Healthcare 
Life Sciences) connected to an Agilent 1200 HPLC system (Agilent, Santa Clara, 
CA, USA). The column was pre-calibrated with dextran standards. 75 μL of sample 
was injected, eluted with 50 mM ammonium acetate and monitored using an 
evaporative light scattering detector (ELSD). 
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2.7. Glycosyl composition analysis 
Glycosyl composition analysis was performed by CCRC. Gas 
Chromatography/Mass spectrometry (GC/MS) analysis of per-O-trimethylsilyl 
(TMS) derivatives of the methyl glycosides was carried out as previously 
described.22-24 Briefly, 300 μg CGP-6-f2 was mixed with 20 μg inositol as internal 
standard and subjected to methanolysis using 1 M methanolic HCl at 80 C for 17 h, 
followed by re-N-acetylation with pyridine and acetic anhydride in methanol. The 
sample was then per-O-trimethylsilylated by treatment with Tri-Sil reagent (Thermo 
Scientific, Waltham, MA, USA) at 80 C for 0.5 h. GC/MS analysis of the TMS 
methyl glycosides was performed on an Agilent 7890A GC interfaced to a 5975C 
Mass Selective Detector (MSD, Agilent) using an Agilent DB-1 fused silica 
capillary column (30 m  0.25 mm I.D., Agilent). The absolute configuration of each 
monosaccharide was determined by comparing TMS (+)-2-butyl derivatives to 
authentic monosaccharide derivatives on GC/MS as previously described.25,26 The 
GC oven temperature was held at 80 °C for 2 min, ramped linearly to 140 °C at 
20 °C/min, then to 200 °C at 2 °C/min, and to 250 °C at 30 °C/min. The glycosyl 
composition was determined by comparison to the retention time of monosaccharide 
standard TMS derivatives.  
 
2.8. Glycosyl linkage analysis 
Glycosyl linkage analysis was performed by CCRC as previously described.24 Briefly, 
CGP-6-f2 was dissolved in 200 μL DMSO and stirred overnight. The sample was 
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initially permethylated by treatment with potassium methylsulfinylmethylide and 
methyl iodide.22 The permethylated sample was hydrolyzed by 2 M trifluoroacetic acid 
(TFA) at 120 °C for 2 h, reduced by sodium borodeuteride, and acetylated by acetic 
anhydride and TFA. The resulting partially methylated alditol acetates (PMAAs) were 
analyzed by GC/MS using a Supelco sp-2330 fused silica capillary column (30 m  
0.25 mm I.D., Sigma-Aldrich). The oven temperature was held at 80 °C for 2 min and 
raised linearly to 170 °C at 30 °C/min, then to 240 °C at 4 °C/min, and held for 5 min. 
The electro-impact (EI) fragmentation patterns of PMAAs were compared to the 
PMAA standards EI fragmentation database. 
 
2.8. De-esterification 
The de-esterification of CGP-6-f2 was performed as previously described.27 Briefly, 
20 mg of CGP-6-f2 was dissolved in 1 mL distilled water. The pH was titrated to 12.0 
by 0.1 M NaOH with constant agitation. The vial was sealed and stirred at 0 °C for 24 
h. The pH of solution was then adjusted to 4.0 by drop-wise addition of 0.1 M HCl. 
The sample was then desalted and lyophilized.  
 
2.9. Nuclear magnetic resonance spectroscopy 
The samples were deuterium exchanged three times by D2O shake and dissolved in 
D2O containing 1μL DMSO as reference (δ 2.71/39.4 ppm). One dimensional 1H and 
13C NMR spectra, as well as two-dimensional COSY, TOCSY, NOESY, HSQC and 
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HMBC NMR spectra were obtained on a Varian 500 MHz NMR spectrometer 
(Agilent) with 5 mm OneNMR probe at 50 °C.   
 
2.10. Measurement of intracellular c-di-GMP level of P. aeruginosa 
The effects of ginseng polysaccharide samples on the intracellular c-di-GMP level of 
P. aeruginosa were analyzed by University of Copenhagen as described previously by 
Rybtke et al.28 Briefly, genes of pelA, pslBCD with or without wspF were deleted 
from wide-type P. aeruginosa PAO1 to get the background strains of ∆pelpsl and 
∆pelpslwspF in relation to different cellular concentrations of c-di-GMP. Deletion of 
wspF causes continuous activation of DGC WSpR, resulting elevated levels of 
c-di-GMP. Deletions of pel and psl disable P. aeruginosa to produce extracellular 
polysaccharides pel and psl that cause bacterial cells to aggregate and lead to an 
inaccurate cell density measurement. The reporter strains monitoring c-di-GMP were 
constructed based on these two background strains. The plasmid of pcdrA-gfp, a 
cyclic-di-GMP-responsive promoter, was introduced by transcriptional fusion into the 
background stains and the intracellular level of c-di-GMP would be readout according 
to the presented fluorescent intensity. The P. aeruginosa PAO1 reporter strains were 
grown at 37 °C with shaking at 185 rpm. 200 µl of culture were transferred into each 
well of a 96-well microtiter plate. With addition of testing samples, the plates were 
incubated for approximately 22 h in a Tecan Infinite Pro2000 (Männedorf, 
Switzerland) plate reader at 37 °C and measured optical density (OD) at 600 nm and 
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fluorescence (490 nm excitation, 515 nm emission) every 30 min. Fluorescence 
intensity units (FIU) were normalized to OD600 in order to offset the effects from 
alteration of bacterial growth.   
 
2.11. In vivo biofilm dispersal effects of ginseng polysaccharides 
Silicone implants were prepared as described previously by Christensen et al29 with 
modifications. A centrifuged precipitate of P. aeruginosa cells from overnight culture 
was re-suspended in 0.9 % NaCl to an OD600 of 0.1 (~10
8 CFU/ml). The prepared 
silicone tubes (half of tube, length, 3 mm; I.D., 4 mm; O.D., 6 mm) were placed into 
24-well plate containing 1 ml of bacterial suspension (OD600 = 0.1) per well, and were 
shaken at 37 °C at 200 rpm overnight to allow bacterial cells attach the surface of 
silicon tubes. The silicon tubes were washed three times with 0.9 % saline. Female 
BALB/c mice, aged at 9 weeks (Taconic M&B A/S, Denmark), were placed ventral 
side up after subcutaneous anaesthesia and made an incision of approximate 5 mm in 
left groin area to expose peritoneal cavity after disinfection. The silicon implant was 
placed into the peritoneal cavity. The incision was closed with a suture, and healed 
without complications. 
 
After 24 h inoculation, mice were treated intraperitoneally with testing samples 
(0.5% CGP/CGP-6 or 0.9% NaCl) at three time points, 0, 4 and 8 h. Mice were 
sacrificed at 0, 4, 8 and 24 h after treatments. Silicon tubes and spleens were 
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collected for analyzing bacteriology. The spleens were homogenized individually in 
3 ml phosphate-buffered saline (PBS). The silicone implants were sonicated 
(Bransonic model 2510, Branson Ultrasonic Corporation, USA) for 5 min twice with 
5 min degas interval to detach bacteria from the silicon tubes. 100 μL bacterial 
suspensions were serially diluted and plated on blue agar plates for the 
determination of CFU after incubation at 37 °C overnight. 
 
3. Results 
3.1. Bioassay-guided fractionation of ginseng polysaccharides 
The crude ginseng polysaccharide (CGP) at five concentrations (serial two times 
dilutions from 0.25% to 0.15%) were incubated with P. aeruginosa reporter strain in 
microtiter plates and the intracellular levels of c-di-GMP were measured by recording 
fluorescent readout every 30 min and normalized to OD600. Figure 5 showed that CGP 
had a concentration-dependent inhibitory effect on the c-di-GMP level, among which at 
15 h 0.25 % of CGP treated group had approximate 40% lower c-di-GMP level 
compared to the untreated group.  
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Figure 5. Effect of various concentrations of CGP on the intracellular c-di-GMP 
level of P. aeruginosa c-di-GMP reporter strain. 
 
Therefore, CGP was further fractionated and screened for molecules having inhibitory 
effects of c-di-GMP level. CGP was firstly separated using step-gradient anion 
exchange chromatography (Figure 3). Seven major fractions were generated and 1 
mg/mL of each fraction was tested for their inhibition on c-di-GMP level. Figure 6 
showed that at 1 mg/mL, CGP-4, CGP-5 and CGP-6 showed comparable or better 
activity than CGP tested at 5 mg/mL and 2.5 mg/mL, among which CGP-6 showed the 
most reduction in c-di-GMP level by over 50%. Therefore, CGP-6, obtained from the 
0.4 M NaCl elution, was further investigated and accounted for 5.8% of the CGP 
dried weight.   
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After further gel permeation chromatography (Figure 4), two fractions, one neutral 
fraction CGP-6-f1 (7.9%) with relatively high molecular weight and one acidic 
fraction CGP-6-f2 (70%) with relatively low molecular weight, were obtained. As the 
primary component of CGP-6, CGP-6-f2 at six concentrations (serial two times 
dilutions from 5.0 mg/mL to 0.15 mg/mL) were evaluated for their effects on the P. 
aeruginosa c-di-GMP level (Figure 7). Within the range of concentrations tested, 
CGP-6-f2 showed concentration-dependent activity. 5.0 mg/mL CGP-6-f2 decreased 
c-di-GMP level to 30% at 15 h and 50% reduction of c-di-GMP level was achieved at as 
low as 0.6 mg/mL. 
 
Figure 6. Effect of CGP (5 mg/mL), CGP (2.5 mg/mL), CGP-1 (1 mg/mL), 
CGP-2 (1 mg/mL), CGP-3 (1 mg/mL), CGP-4 (1 mg/mL), CGP-5 (1 mg/mL), 
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CGP-6 (1 mg/mL) and CGP-7 (1 mg/mL) on the intracellular c-di-GMP level of 
P. aeruginosa c-di-GMP monitor strain. 
 
 
 
Figure 7. Effect of various concentrations of CGP-6-f2 on the intracellular 
c-di-GMP level of P. aeruginosa c-di-GMP monitor strain. 
 
3.2. Effect of ginseng polysaccharides on P. aeruginosa in vivo 
Because one of major consequences of decreased level of c-di-GMP is causing 
bacterial biofilm dispersal, the in vivo effects of ginseng polysaccharides on mature 
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bacterial biofilm were analyzed using mice with intraperitoneal insertion of silicone 
tubes attached with P.aeruginosa PAO1. After 24 h formation of biofilm on the silicon 
tube, testing samples were injected into the intraperitoneal cavity. Molecules 
decreasing c-di-GMP level would then cause bacterial cells within biofilm to disperse 
and be transferred to spleen for clearing out the body therefore a lower bacterial cell 
count from the silicon tube but a higher bacterial cell count from the spleen. In this 
assay, due to limited quantity of CGP-6-f2, only CGP and CGP-6 were tested. In 
Figure 8, CGP-6 treated groups showed significantly lower bacterial cell counts from 
silicon tubes at 4, 8, and 24 h after treatment and significantly higher bacterial cell 
counts in spleens at 4, and 8 h after treatment when compared to the groups treated with 
0.9% NaCl. At 24 h, there is no significant difference in bacterial cell counts from 
spleen between CGP-6 group and control, suggesting that the bacterial cells have been 
efficiently cleared out within 24 h. In CGP treated group, there were fewer bacteria 
from silicon tubes at 8 and 24 h and more bacteria in spleens at 4 and 8 h compared to 
the control group.  These data suggested that both of CGP and CGP-6 showed in vivo 
dispersal effect. In addition, compared to CGP, CGP-6 treatment showed significantly 
faster bacterial dispersal on silicone tubes as early as at 4 h and lower bacterial cell 
number on the silicon after 24 h treatment. 
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Figure 8. Bacteriology at different times after treatments for silicone tubes 
(up-panel) and spleens (down-panel): Inocula (◑); Group treated with 0.9% 
Sodium Chloride (○); Group treated with CGP (◇); Group treated with CGP-6 
(△). 
 
3.3. Structural characterization of CGP-6-f2 
3.3.1 Homogeneity and molecular weight 
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The homogeneity of CGP-6-f2 was analyzed by HPSEC on a Superose 12 column and 
eluted with 50 mM ammonium acetate. The elution profile (Figure 9) showed two 
peaks. The major peak (CGP-6-f2) eluted around 10 minutes was estimated to be 
70,000 Da. The second peak eluted around 20 minutes was estimated to be very small 
and very likely to be salt.  
 
 
Figure 9. HPSEC elution profile of CGP-6-f2 on a Superose 12 column. 
 
3.3.2 Glycosyl composition analysis 
The glycosyl composition and absolute configuration analysis showed that CGP-6-f2 
was composed primarily of D-galacturonic acid (D-GalA, 67.0%), L-Arabinose 
(L-Ara, 13.3%), L-Rhamnose (L-Rha, 9.2%), D-Galactose (D-Gal, 9.3%) and some 
minor components (Fucose 0.4%, Xylose 0.2%, Glucuronic acid 0.4% and Glucose 
0.2%).  
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3.3.3. Glycosyl linkage analysis 
For the glycosyl linkage analysis, CGP-6-f2 was permethylated, hydrolyzed and 
acetylated to have a mixture of partially methylated alditol acetates (PMAAs). In 
GC/MS analysis, each PMAA was identified by comparison of retention time and 
fragmentation pattern with standards. The glycosyl linkages present in CGP-6-f2 were 
listed in Table 1.  
 
Table 1. Major glycosyl linkages presented in CGP-6-f2 
Glycosyl composition and linkage analyses suggested that CGP-6-f2 belongs to 
pectins that are important structural components of plant primary cell wall.30. Unlike 
polymers with single repeating unit, pectins are heteropolysaccharides that often 
contain a combination of various backbones and side chains.31-35 The heterogeneous 
backbone was composed of a combination of homogalacturonan (HG) with repeating 
4)-α-GalpA-(1, and rhamnogalacturonan (RG) with alternate disaccharide unit 
4)-α-GalpA-(1,2)-α-L-Rhap-(1,.36 Galactan, arabinan and arabinogalactan are the three 
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most common side chains that are exclusively branched at C-4 of rhamnosyl residues. 
30,37 
 
3.3.4. NMR analysis 
1H and 13C NMR resonances allowed assignment of nine different sugar residues and 
are represented as residues A-I (see Table 2).  
 
The 1H NMR spectrum of CGP-6-f2 (Figure 10) revealed four major anomeric proton 
signals, which were assigned as, H-F1 (δ 5.11), H-E1 (δ 5.07), H-G1 (δ 4.95) and 
H-H1 (δ 4.90). According to HSQC (Figure S3), anomeric carbons for residues E, F, 
G and H were assigned as C-F1 (δ 99.81), C-E1 (δ 99.50), C-G1 (δ 100.74) and C-H1 
(δ 100.49). The chemical shift of a pyranosyl anomeric carbon in an α-linkage (~δ 
97-101) is generally more upfield than β-linkage (~δ 97-105).38 The chemical shifts of 
a furanosyl anomeric carbon are generally more downfield (~δ 106-109) than 
pyranosyl anomeric carbons.39 Therefore, residues E, F, G, H were assigned to 
α-linked GalpA, which is the most abundant glycosyl residue. The intense resonance 
at δ 3.80 in the 1H NMR spectrum and δ 53.38 in the 13C NMR spectrum (Figure 11) 
were assigned to the -CH3 in the methyl esterified GalpA (GalpAMe), which was 
further confirmed by HMBC correlations at δ 3.80/171.25 and δ 3.80/171.27 (Figure 
S4). The carbonyl carbons at δ 171.25 and δ 171.27 were assigned to GalpAMe, 
which are slightly more upfield than the carbonyl carbons of GalpA at δ 175.39 and δ 
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175.67. The two HSQC resonances at δ 2.17/21.08 and δ 2.08/20.76 suggested that 
some residues were acetylated. 
 
For residue F, the COSY (Figure S2) correlations at δ 5.11/3.74, δ 3.74/3.99, δ 
3.99/4.46, δ 4.46/5.11, and a spin system in the TOCSY spectrum along the sugar ring 
were observed. Accordingly, the carbon chemical shifts of C-F2, C-F3, C-F4 and 
C-F5 were assigned by HSQC correlations at δ 3.74/68.60, δ 3.99/68.69, δ 4.46/78.83 
and δ 5.11/71.02, respectively. The HMBC correlation at δ 5.11/171.27 suggested that 
residue F was methyl esterified. The downfield chemical shift of C-F4 at δ 78.83 
indicated its linkage at position 4. In total, the evidence points to residue F as a 
4-α-D-GalpAMe. Similarly, for residue G, 1H resonances of residue protons H-G2, 
H-G3, H-G4 and H-G5 were assigned as δ 3.72, δ 3.98, δ 4.45 and δ 5.05, 
respectively. Accordingly, the carbon chemical shifts of C-G2, C-G3, C-G4 and C-G5 
were assigned by HSQC correlations at δ 3.72/68.64, δ 3.98/69.25, δ 4.45/79.30 and δ 
5.05/71.04, respectively. The HMBC correlation at δ 5.05/171.25 indicated that 
residue G was also methyl esterified, and the C-G4 resonance at δ 79.30 indicated 
residue G was linked at position 4. All the evidences above suggested that residue G 
was also 4-α-D-GalpAMe. However, slight difference in chemical shifts of residue F 
and G suggested their different chemical environments within the polymeric structure. 
 
For residue E, the COSY correlations at δ 5.07/3.75, δ 3.75/3.98, δ 3.98/4.40, δ 
4.40/4.70, and a spin system along the sugar ring from TOCSY were detected. 
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Accordingly, C-E2, C-E3, C-E4 and C-E5 were assigned by HSQC correlations at δ 
3.75/68.72, δ 3.98/69.47, δ 4.40/78.54, and δ 4.70/71.88, respectively. The HMBC 
correlation at δ 4.70/175.67 indicated that residue E was a galacturonic acid (GalpA). 
The chemical shift of C-E4 at δ 78.54 indicated residue E was linked at position 4. All 
together residue E was assigned as 4-α-D-GalpA. Similarly, for residue H, 1H 
resonances of residue protons H-H2, H-H3, H-H4 and H-H5 were assigned as δ 3.73, 
δ 3.96, δ 4.39 and δ 4.68, respectively. Accordingly, C-H1, C-H2, C-H3, C-H4 and 
C-H5 were assigned by HSQC correlations at δ 3.73/68.64, δ 3.96/69.25, δ 4.39/79.15 
and δ 4.68/71.90, respectively. The HMBC correlation at δ 4.68/175.39 indicated that 
residue H was also GalpA. The chemical shift of C-H4 at δ 79.15 indicated residue H 
was linked at position 4. Together, the evidence above is consistent with residue H as 
4-α-D-GalpA.  
 
 
Figure 10. 1H NMR spectrum of CGP-6-f2. (D2O, 500 MHz) 
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Figure 11. 13C NMR spectrum of CGP-6-f2. (D2O, 125 MHz) 
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The TOCSY spectrum (Figure S1) further revealed four additional spin systems with 
anomeric protons assigned as H-A1 (δ 5.15), H-B1 (δ 5.10), H-C1 (δ 5.08) and H-D1 
(δ 4.62). In the case of residue D, COSY correlations at δ 4.62/3.68, δ 3.68/3.76, δ 
3.76/4.15, δ 4.15/3.70 and δ 3.70/3.74 were detected. Accordingly, HSQC spectrum 
revealed carbon resonances at δ 104.85, δ 72.43, δ 73.77, δ 78.00, δ 74.96 and δ 
69.00. The chemical shift of C-D4 at δ 78.00 suggested that residue D was linked at 4 
position, and the C-D1 resonance at δ 104.85 indicated that residue D was β-linked. 
Therefore the residue D was assigned as 4-β-D-Galp.  
 
For residues A, B and C, the HSQC correlations at δ 5.15/107.69, 5.10/108.05 and δ 
5.08/108.05 were assigned to the correlation between anomeric proton and carbon of 
A, B and C, respectively. Further downfield carbon chemical shifts indicated that they 
were all furanosyl residues and α-linked.32 From COSY and TOCSY spectra, residue 
A protons were assigned as H-A1 (δ 5.15), H-A2 (δ 4.13), H-A3 (δ 3.95), H-A4 (δ 
4.03), and H-A5 (δ 3.81). Residue B protons were assigned as H-B1 (δ 5.10), H-B2 (δ 
4.28), H-B3 (δ 4.09), H-B4 (δ 4.30) and H-B5 (Ha: δ 3.83, Hb: δ 3.93). Residue C 
protons were assigned as H-C1 (δ 5.08), H-C2 (δ 4.12), H-C3 (δ 4.02), H-C4 (δ 4.21), 
H-C5 (Ha: δ 3.79, Hb: δ 3.88). Furanosyl residue A, B and C can be attributed to the 
arabinofuranosyl residues. From HSQC spectrum, the rest of carbon signals of residue 
A, B and C were assigned as C-A2 (δ 81.63), δ 77.03, δ 84.41, and δ 61.48; C-B2 (δ 
79.66), C-B3 (δ 82.83), C-B4 (δ 82.03), and C-B5 (δ 67.14); C-C2 (δ 81.63), C-C3 (δ 
77.18), C-C4 (δ 82.69), and C-C5 (δ 66.89). C-A5 at δ 61.48 indicated residue A was 
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a terminal arabinofuranosyl residue (t-Araf). The more downfield C-B3, C-B5 and 
C-C5 suggested that residue B was 3,5-linked arabinofuranosyl residue (3,5-Araf) and 
residue C was 5-linked arabinofuranosyl residue (5-Araf).  
 
Although anomeric proton or carbon was not initially detected for the Rhap, they were 
later identified from NMR spectra of de-esterified CGP-6-f2 and assigned as H-I1 (δ 
4.77) and C-I1 (δ 101.08). In addition, 1H resonance at δ 1.24 and its corresponding 
13C resonance at δ 17.12 were characteristic to the methyl group of Rhap. For residue 
I, from the COSY spectrum of de-esterified CGP-6-f2 (Figure S7), the H-I2, H-I3, 
H-I5 and H-I6 were assigned as δ 4.57, δ 3.95, δ 3.77 and δ 1.24, respectively. 
Accordingly, the carbons of residue I were assigned by the HSQC spectrum of 
de-esterified CGP-6-f2 (Figure S8) at δ 4.77/101.08, δ 4.57/79.73, δ 3.95/69.00, δ 
3.77/70.54 and δ 1.24/17.12. The chemical shift of C-I2 at δ 79.73 indicated that 
residue I was linked at position 2. The anomeric chemical shifts of residue I1 at δ 
4.77/101.08 indicated that residue I was β-linked.33,40 Thus, residue I was assigned as 
2-β-L-Rhap.  
 
The sequences of the repeating units were determined by NOESY (Figure S5) and 
HMBC experiments. The correlations at δ 5.07/4.40 (H-E1/H-E4) in NOESY and δ 
5.07/78.54 (H-E1/C-E4) in HMBC were detected, which suggested that residue E was 
mostly connected to identical residues at position 4. The correlations at δ 4.90/4.46 
(H-H1/H-F4) and δ 5.11/4.39 (H-F1/H-H4) in NOESY, together with δ 4.90/78.83 
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(H-H1/C-F4) and δ 5.11/79.15 (H-F1/C-H4) in HMBC were detected, suggesting that 
residue F and H were mostly linked alternately through connections at position 4. The 
correlations at δ 4.95/4.45 (H-G1/H-G4) in NOESY and δ 4.95/79.30 (H-G1/C-G4) in 
HMBC were also observed, which is consistent with G residues G being connected to 
other G residues at position 4. The similarity in chemical shifts among the 
1,4-α-D-GalpA and its methyl esters in addition with their alternate pattern suggested 
that these four residues are lined in the main chain with slightly different chemical 
environment from esterifications and acetylations. It could also be supported by the 
1H spectrum of the de-esterified CGP-6-f2 (Figure S6), since there was only one 
GalpA-type residue following de-esterification. Due to the complexity in the original 
NMR spectra, the following correlations can only be observed in de-esterified 
CGP-6-f2 NMR spectra. The correlations at δ 4.62/4.15 (H-D1/H-D4) in NOESY 
(Figure S10) indicated that residue D was connected to other D residues as a galactan 
side chain. The correlations at δ 5.15/82.83 (H-A1/C-B3), δ 5.10/66.89 (H-B1/C-C5) 
and δ 5.08/67.14 (H-C1/C-B5) from HMBC (Figure S9) suggested that residue A 
connected to B residues at position 3 and residues B and C connected to each other at 
position 5.  
 
Thus, the backbone structure of CGP-6-f2 contains a combination of two repeating 
units, namely -4)-α-D-GalpA-(1- and -4)-α-D-GalpA-(1,2)-α-L-Rhap-(1-. Side chains 
of CGP-6-f2 are partially branched at position 4 on Rhap by galactan and arabinan. 
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The combined structural features of CGP-6-f2 are consistent with a RG-I type pectic 
polysaccharide30,41 and a tentative structure is proposed as in Figure 12. 
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4. Discussion 
The Asian ginseng (Panax ginseng Meyer) is one of the most popular herbal 
medicines and the root has been traditionally consumed in East Asia to improve 
human immune system.42,43 Recent studies on ginseng have suggested its multiple 
health benefits including physical performance improvement44, immunomodulatory45, 
anti-cancer46 and anti-hypertension activities47. Today, over 200 molecules have been 
identified from Panax ginseng including peptides, amino acids, ginsenosides and 
polysaccharides.48 Ginsenosides are a unique group of triterpene saponins isolated 
from ginseng, among which a ginsenoside compound K has exhibited anti-alllergic49, 
anti-diabetic50, anti-aging51 and anti-inflammatory52 effects. Because ginseng root is 
traditionally processed by boiling with hot water, components from its aqueous 
extract such as polysaccharides have attracted great interests. Many kinds of 
polysaccharides have been isolated from Panax ginseng such as Ginsan53, PGP2a54, 
and PGPW155 but very few of the intact structures were characterized.  
 
Due to the key role of biofilm in persistent bacterial infections, increasing attention has 
been drawn to the nature of biofilm and searching for molecules that inhibit the biofilm 
formation. Interestingly, certain polysaccharides have been found to inhibit P. 
aeruginosa biofilm formation. Examples include capsular polysaccharide K2 from the 
E. coli CFT07356, r-EPS from bacterium Lactobacillus acidophilus A457, PI80 EPS 
from Streptococcus phocae58 and A101 from Vibrio sp. QY10159. In addition, previous 
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study60 on Panax ginseng aqueous extract has exhibited biofilm prevention and 
dispersal effects.  
 
However, the mechanism of these anti-biofilm complex carbohydrates is still unknown. 
In this study, a pectic polysaccharide derived from Panax ginseng was found to 
decrease P. aeruginosa intracellular c-di-GMP level. Inhibition of c-di-GMP 
production will cause downregulation of biosynthesis of biofilm matrix 
polysaccharides as well as upregulation of production of motility-involved appendages. 
Therefore, the anti-biofilm effects of ginseng pectic polysaccharide are very likely 
through inhibition of c-di-GMP production. Further in vivo investigation of its effect in 
dispersing preformed biofilm suggests its efficacy in potential application in treating 
biofilm-associated infections.  
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Figure S1. TOCSY spectrum of CGP-6-f2. (D2O, 500 MHz) 
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Figure S2. COSY spectrum of CGP-6-f2. (D2O, 500 MHz) 
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Figure S3. HSQC spectrum of CGP-6-f2. (D2O, 500 MHz) 
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Figure S4. HMBC spectrum of CGP-6-f2. (D2O, 500 MHz) 
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Figure S5. NOESY spectrum of CGP-6-f2. (D2O, 500 MHz) 
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Figure S6. 1H NMR spectrum of de-esterified CGP-6-f2. (D2O, 500 MHz) 
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Figure S7. COSY spectrum of de-esterified CGP-6-f2. (D2O, 500 MHz) 
 
. 
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Figure S8. HSQC spectrum of de-esterified CGP-6-f2. (D2O, 500 MHz) 
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Figure S9. HMBC spectrum of de-esterified CGP-6-f2. (D2O, 500 MHz) 
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Figure S10. NOESY spectrum of de-esterified CGP-6-f2. (D2O, 500 MHz) 
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Abstract 
Maple syrup is a widely consumed plant-derived natural sweetener produced by 
concentrating xylem sap collected from certain maple (Acer) species. During 
thermal evaporation of water, natural phytochemical components are concentrated in 
maple syrup. The polymeric components from maple syrup were isolated by ethanol 
precipitation, dialysis, and anion exchange chromatography and structurally 
characterized by glycosyl composition analysis, glycosyl linkage analysis, and 
nuclear magnetic resonance spectroscopy. Among the maple syrup polysaccharides, 
one neutral polysaccharide was characterized as inulin with a broad molecular 
weight distribution, representing the first isolation of this prebiotic carbohydrate 
from a xylem sap. In addition, two acidic polysaccharides with structural similarity 
were identified as arabinogalactans derived from rhamnogalacturonan type I pectic 
polysaccharides. 
 
Keywords: Maple syrup, polysaccharide, inulin, arabinogalactan. 
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Introduction 
Maple syrup is a natural sweetener produced from concentrated xylem sap collected 
from certain maple (genus Acer) species, primarily the sugar maple (Acer 
saccharum Marsh).1,2 The sugar maple is widely distributed in the northeastern 
region of North America with the majority of maple syrup being commercially 
produced in this region, primarily in Quebec, Canada.2 Maple syrup is of great 
economical importance to the eastern North American region since it is the largest 
commercially produced and consumed tree-sap derived food product worldwide.3 As 
a commercial product that requires minimal processing (thermal evaporation), maple 
syrup contains several phytochemicals, primarily (poly)phenolics, which have been 
reported to impart a variety of biological effects. While sucrose is the major 
component in maple syrup, this plant-derived natural sweetener also contains simple 
sugars (glucose and fructose), amino acids, minerals (e.g. potassium, calcium, and 
magnesium), vitamins (e.g. B2 and niacin), organic acids (e.g. succinic and fumaric 
acid), and complex carbohydrates.1 Among the various chemical constituents 
reported from maple syrup, biological evaluation has primarily focused on its 
diverse phenolic components. For instance, phenolic-enriched extracts of maple 
syrup have been reported to show anti-oxidant, anti-mutagenic, anti-cancer, 
anti-inflammatory and anti-neurodegenerative effects.3-7  
 
In contrast to the phenolic components of maple syrup, molecules of larger 
molecular weight, such as oligosaccharides and polysaccharides, have been less 
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investigated. Previous reports have identified dextran, arabinogalactan and 
rhamnogalacturonan in maple syrup.8,9 These biopolymers are derived from primary 
cell wall components of maple trees.  
 
In this study, an inulin type fructan has been isolated for the first time from maple 
syrup. Inulins are commercially extracted from chicory root and used as dietary fiber 
in the food industry.10,11 As one type of poly-fructan, the inulin structure features a 
polydisperse molecular size and is a non-branched polymer consisting exclusively of 
β-1,2-frucosyl linkages between fructosyl residues and a terminal glucose.12,13 Inulin 
is generally believed to be synthesized from sucrose by fructosyltransferases and to 
serve as energy storage.10 Because the linkage type within inulin is resistant to 
hydrolysis by human digestive enzymes, inulin is considered a non-digestive 
polysaccharide, which makes its biological effects reside in its interactions with the 
human lower gastrointestinal tract, primarily in the colon.10,14,15 Inulin-type fructans 
have been reported to benefit immune systems by interacting with gut lymphoid 
tissues,16,17 colon health by selectively promoting the growth of bifidobacteria and 
lactobacilli probiotic bacteria,18,19 and cardiovascular systems by decreasing 
cholesterol and triglyceride levels in serum.10,20 
 
Materials and methods 
Materials 
Maple syrup (grade C, 40 L) was shipped frozen to our laboratory by the Federation 
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of Maple Syrup Producers of Quebec (Longueuil, Quebec, Canada) and stored at 
-20 °C. Solvents for nuclear magnetic resonance (NMR) spectroscopy were 
purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA). All other 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise 
specified. 
 
Total carbohydrate content determination 
Total carbohydrate content assay was performed in microtiter plates using a 
colorimetric assay as previously described.21 Briefly, in each well of a 96-well 
microtiter plate, 30 μL of each fraction was added to 100 μL concentrated sulfuric 
acid and 20 μL 5% phenol solution. The microtiter plates were then incubated at 
90 °C for 5 min and recorded for absorbance at490 nm using a Spectramax M2 
microplate reader (Molecular Devices, Sunnyville, CA). Glucose was used as the 
standard for the total carbohydrate content assay. 
 
Extraction of maple syrup polysaccharides 
Maple syrup (300 mL, 412 g) was first diluted with 450 mL distilled water followed 
by 95% ethanol to achieve a 60% ethanol/water solution. Crude polysaccharides 
were precipitated at -20 °C overnight. Precipitates were centrifuged and dried by 
sequential solvent exchanges with 100% ethanol and ether. The supernatants were 
combined and diluted with 95% ethanol to create an 80% ethanol/water solution, 
resulting in additional precipitation of polysaccharides as described above. Dry 
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precipitates were re-dissolved in 50 mL distilled water and dialyzed through a 
membrane with molecular weight cut-off (MWCO) of 12,000-14,000 (Spectrum 
Laboratories, Inc., Rancho Dominguez, CA) against distilled water with stirring for 
48 h. The retained polysaccharides were lyophilized to obtain Fr.1 (30 mg) from the 
60% ethanol precipitation and Fr.2 (23 mg) from the 80% ethanol precipitation, 
respectively.  
 
Purification of polysaccharides 
Polysaccharides were fractionated on a Hiprep Q Sepharose anion exchange column 
(100 mm × 16 mm i.d., GE Healthcare Life Sciences, Pittsburgh, PA). 20 mg of Fr.1 
were firstly eluted with 65 mL distilled water and then a linear gradient of NaCl (0-1 
M) for 200 mL at 5 mL/min (Figure 1). 20 mg of Fr.2 were subjected to the same 
anion exchange chromatography. The eluate was collected in 5 mL fractions and 
pooled by total carbohydrate content. All fractions were dialyzed (MWCO 
12,000-14,000) against distilled water with stirring for 48 h and lyophilized to obtain 
Fr.1-1 (10.5 mg, 0.004%, w/w), Fr.1-2 (5.5 mg, 0.002%, w/w), Fr.2-1 (1.1 mg, 
0.0003%, w/w) and Fr.2-2 (8.3 mg, 0.002%, w/w).  
 
Homogeneity and molecular size 
The homogeneity and molecular sizes of polysaccharides were analyzed using a 
high performance size exclusion column TSK-gel G3000PW (300 mm × 7.5 mm i.d., 
TOSOH, Tokyo, Japan) at 40 °C on a Hitachi LaChrom Elite HPLC (Hitachi, Tokyo, 
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Japan) equipped with a refractive index (RI) detector. Standard curves for molecular 
size determinations were generated using dextran standards (1000, 5000, 12,000, 
25,000, 50,000, 80,000 and 150,000 Da). 
 
Glycosyl composition analysis 
Glycosyl composition analysis was accomplished with polysaccharide acid 
hydrolysates using high performance anion exchange chromatograph with pulsed 
amperometric detection (HPAEC-PAD) as previously described.22 Briefly, 500 μg of 
Fr.1-1, Fr.1-2, Fr.2-1 and Fr.2-2 were hydrolyzed with 200 μL of 2M trifluoroacetic 
acid (TFA) in sealed ampoules at 120 °C for 2 h. The resulting hydrolysates were 
dried with a stream of nitrogen gas. 200 μL of isopropanol was added and dried by 
nitrogen gas. This process was repeated twice to remove residual TFA. Due to the 
fragility of fructose under acidic conditions, an alternate mild acid hydrolysis for 
Fr.1-1 was performed.23 200 μg Fr.1-1 were hydrolyzed with 200 μL 0.2% TFA in 
sealed ampoules at 90 °C for 1 h.  
 
Hydrolysates from both hydrolytic reactions were separated on a Hamilton RCX-30 
column (250 mm × 4.6 mm i.d., Metrohm, Herisau, Switzerland) on a 9600 
Professional IC Vario ion chromatograph with a 945 Professional Vario IC pulsed 
amperometric detector (Metrohm, Herisau, Switzerland). Monosaccharide standard 
curves for fucose, arabinose, xylose, rhamnose, galactose, glucose, fructose, 
galacturonic acid and glucuronic acid were created by HPAEC-PAD on the same 
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column. Each monosaccharide and uronic acid was dissolved in distilled water at six 
concentrations (10, 20, 50, 100, 500, and 1000 ppm) and an aliquot of 10 μL was 
injected. Standard curves were created by plotting area under curves (AUCs) with 
concentrations. For analyzing fucose, arabinose, xylose, rhamnose, galactose and 
glucose, the column was eluted with isocratic 16 mM NaOH over 40 min. For 
analyzing fructose, the column was eluted with isocratic 100 mM NaOH over 20 
min. For analyzing glucuronic and galacturonic acids, the column was eluted with 
isocratic 20 mM sodium acetate in 100 mM NaOH over 20 min.  
 
Glycosyl Linkage Analsysis 
Glycosyl linkage analysis was performed as previously described.24 800 μg Fr.1-1, 
Fr.1-2, Fr.2-1 and Fr.2-2 were stirred overnight in 300 μL dimethyl sulfoxide 
(DMSO). Intact polysaccharides were thrice permethylated in anhydrous DMSO 
solution of NaOH and methyl iodide for 20 min. The permethylated polysaccharides 
were extracted with methylene chloride and then hydrolyzed with 200 μL of 2M 
TFA at 120 °C for 2 h. Permethylated Fr.1-1 was hydrolyzed with 200 μL 0.2% TFA 
at 90 °C for 1 h. Hydrolysates were dried with N2 gas and residual TFA was 
removed by repeatedly drying with isopropanol. The partially methylated 
hydrolysates were reduced with NaBD4 and then acetylated with acetic anhydride. 
The resulting partially methylated acetic acetates (PMAAs) were analyzed on a 
Series 6890 gas chromatography (Agilent Technologies, Santa Clara, CA) coupled 
with a mass selective detector (MSD) on a Supelco SP-2330 capillary column (30 m 
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× 0.25 mm i.d., Sigma-Aldrich). The oven temperature was held at 80 °C for 2 min 
and increased to 170 °C at 30 °C/min, then to 240 °C at 4 °C/min, and held for 5 
min.  
 
NMR 
The 1H and 13C NMR spectra and two-dimensional COSY, TOCSY, HSQC and 
HMBC data were recorded on a Varian 500 MHz NMR spectrometer  equipped 
with a 5 mm OneNMR probe (Agilent Technologies). The samples were D2O 
exchanged twice and dissolved in D2O (0.5 mL, 99.96%). All spectra were recorded 
at 25 °C. 
 
RESULTS AND DISCUSSION 
Crude polysaccharides Fr.1 and Fr.2 were fractionated using a semi-preparative Q 
Sepharose anion exchange column and polysaccharide- enriched fractions were 
pooled based on a total carbohydrate content assay. 21 While subject to few 
interferences, this colorimetric assay is highly sensitive and has wide applicability 
for estimating the carbohydrate contents of plant natural products.22 The elution 
profiles (Figure 1) showed that Fr.1 contained a neutral polysaccharide fraction 
Fr.1-1 and an acidic polysaccharide fraction Fr.1-2. Similarly, Fr.2 also contained a 
neutral polysaccharide fraction Fr.2-1 and an acidic polysaccharide fraction Fr.2-2.  
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Figure 1. The elution profile of Fr. 1by anion exchange chromatography. 
 The molecular sizes of the purified polysaccharide components were analyzed 
by HPSEC-RI. The dispersal of Fr.1-1 across a broad region of elution volume  
indicated that Fr.1-1 was comprised of polydisperse and large molecular weight 
(>12,000 Da) polymers. Elution profiles of Fr.1-2 and Fr.2-2 showed symmetric 
peaks, indicating the molecular weights of Fr.1-2 and Fr.2-2 to be approximately 
140,000 Da and 70,000 Da, respectively. Due to the limited quantity of Fr.2-1 and 
sensitivity of the RI detector, the molecular size of Fr.2-1 was not successfully 
measured. 
 The glycosyl and linkage compositions of the purified polysaccharides were 
evaluated as follows.  Because fructose is easily degraded, Fr.1-1 was hydrolyzed 
with two hydrolytic conditions. Hydrolysis with 2M TFA at 120 °C for 2 h totally 
degraded fructose, leaving only glucose detectable in the HPAEC profile. Mild acid 
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hydrolysis of Fr.1-1 using 0.2% TFA at 90 °C for 1 h was performed to hydrolyze 
the glycosidic bonds between fructose residues and preserve the resulting 
monosaccharides. By comparison to the standard curves, the glycosyl composition 
of Fr.1-1 (Table 1) contained primarily fructosyl (96%) and glucosyl (4%) residues, 
which suggested that Fr.1-1 is a poly-fructan with minor inclusion of glucose.  
 
Glycosyl residue Fr.1-1 Fr.1-2 Fr.2-1 Fr.2-2 
 Mole % 
Rhamnosyl 0 9 0 7 
Arabinosyl 0 35 25 42 
Galactosyl 0 47 35 40 
Glucosyl 4 1 40 2 
Mannosyl 0 1 0 2 
Fructosyl 96 0 0 0 
Galacturonic acid 0 7 0 7 
Table 1. Glycosyl compositions of Fr. 1-1, Fr.1-2, Fr.2-1 and Fr.2-2. 
 
The presence of 2-fructosyl residues indicated that the fructosyl residues were linked 
at position 2, which is characteristic for inulin. Inulin contains a non-branched 
1,2-linked fructosyl backbone and terminates with a glucosyl residue (GFn) (Figure 
2).12 The neutral monosaccharide compositions of Fr.1-2, Fr.2-1 and Fr.2-2 were 
analyzed on HPAEC-PAD and eluted with isocratic 16 mM NaOH for improved 
resolution. Neutral polysaccharide Fr.2-1 was composed of arabinosyl (25%), 
galactosyl (35%) and glucosyl (40%). Together with the presence of a terminal 
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arabinosyl, 3- and 3,6-galactosyl, and 6-glucosyl linkages, Fr.2-1 may be a mixture 
of arabinogalactan and dextran, which has been speculated to be a microbial derived 
polysaccharide.8 Acidic polysaccharides Fr.1-2 and Fr.2-2 hydrolysates were also 
analyzed for their uronic acids (Table 1). Together with their neutral 
monosaccharide compositions, Fr.1-2 and Fr.2-2 appear to share structural similarity. 
The two polysaccharides were primarily composed of terminal and 5-arabinosyl and 
3- and 3,6-galactosyl with a lower percentage of 2,4-rhamnosyl and 4-galacturonic 
acid residues. These results suggest that Fr.1-2 and Fr.2-2 are arabinogalactans 
derived from degradation of acidic rhamnogalacturonan type I (RG-I) pectic 
polysaccharides. These molecules are important plant cell wall components and 
often contain alternate rhamnosyl and galacturonic acid backbones and 
arabinogalactan side chains.25  
 
Figure 2. General chemical structure of inulin.  
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Figure 3. 1H NMR spectrum of Fr. 1-1 (500MHz, D2O).  
 
The structures of the polysaccharides were characterized by NMR analyses. The 
1H NMR spectrum of Fr.1-1 (Figure 3) revealed seven major protons between 3.3 to 
4.2 ppm and a very small anomeric proton signal at 4.8 ppm. The 13C NMR and 
HSQC spectra showed one quaternary carbon at 104.1 ppm, three CH and two CH2, 
which suggested characteristic structural features of the ketonic monosaccharide 
fructose, which lacks an anomeric proton but contains two methylenes at positions 1 
and 6. The chemical shifts of Fr.1-1 were assigned using two-dimensional NMR 
experiments (Table 2). Briefly, with the correlations in COSY, the chemical shifts of 
proton 3-6 in the 2-Fructosyl were assigned as H-3 at δ 4.02, H-4 at δ 3.93, H-5 at δ 
3.79 and H-6 at δ 3.40/3.74. The chemical shifts of carbon 3-6 in the 2-Fructosyl 
were assigned accordingly with correlations in HSQC spectra as C-3 at δ 76.4, C-4 
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at δ 75.3, C-5 at δ 80.2 and C-6 at δ 63.3. The two doublets at δ 3.52 and δ 3.60 
correlate to one carbon at δ 60.0, which were assigned as the proton and carbon 
chemical shifts of the H-1/C-1 methylene in 2-Fructosyl. A correlation was observed 
between C2 and H1 in the HMBC spectrum, which further confirmed that the 
fructosyl residues were linked at position 2. The small proton signal at 4.8 ppm was 
attributed to the anomeric proton of glucose. The 1H NMR spectra of Fr.1-2, Fr.2-1 
and Fr.2-2 showed only proton resonances belonging to carbohydrates (anomeric 
protons, 4.4-5.5 ppm; clustered resonances between 3.4 ppm and 4.0 ppm)26, 
suggesting that only polysaccharides were present in the samples. The proton 
resonances appearing near 1.1 ppm for Fr.1-2 and Fr.2-2 are characteristic for the 
rhamnose methyl group at position 5. However, further investigations on these 
molecules by 2D NMR analyses are needed to better define their complete structural 
features. 
 
Residue H-1/C-1 H-2/C-2 H-3/C-3 H-4/C-4 H-5/C-5 H-6/C-5 
2-Fructosyl 
3.52/3.60 - 4.02 3.93 3.79 3.40/3.74 
60.0 104.1 76.4 75.3 80.2 63.3 
Terminal Glucosyl 
4.82 3.42 3.73 - - - 
- - - - - - 
Table 2. 1H and 13C chemical shift assignments of Fr. 1-1 in parts per million 
(ppm). 
 
 Maple syrup is widely consumed as a functional food in large part because of its 
phenolic constituents which are believed to impart health benefits. For example, 
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quebecol is a phenolic compound from maple syrup27 that possesses 
anti-inflammatory28 and anti-proliferative properties.29 A variety of phenolic 
derivatives from maple syrup demonstrate free radical scavenging activity superior 
to that of vitamin C.3 Several polyphenolic molecules present in maple syrup show 
anti-proliferative effects through arresting cell cycles, suggesting potential effects in 
cancer prevention.30 In addition, in vivo studies on phenolic-enriched maple syrup 
extracts have shown promising therapeutic potential for liver protection,31 
anti-inflammation32 and anti-diabetes.33,34 
 The polysaccharides dextran, arabinogalactan and rhamnogalacturonan have 
been previously identified from maple syrup.8,9 Dextran is a common polysaccharide 
synthesized from sucrose and prominently features repeating units of α-6-linked 
glucose.35 Previous studies8,9 have attributed the glycosyl compositions and 
glycosydic linkages of arabinogalactans and rhamnogalacturonans to partially 
degraded pectins. Pectins are heteropolysaccharides and are one of the major 
structural components of plant cell walls.36 The heterogeneous backbone of pectin is 
composed of homogalacturonan (HG) with repeating 4)-α-GalpA-(1, and 
rhamnogalacturonan (RG) with the alternating disaccharide 
4)-α-GalpA-(1,2)-α-L-Rhap-(1,.37 Arabinogalactan, a major side chain branched at 
C-4 of rhamnosyl residues, contains a linear 6-linked galactan substituted at C-3 
with arabinoses.38  
 Herein, inulin is being reported from maple syrup for the first time. Inulins are 
widely present in several plant families including Liliaceae, Amaryllidaceae, 
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Gramineae, and Compositae. Many edible fruits and vegetables such as banana, 
onion, artichoke, chicory roots, garlic, and leek contain inulin.39 However, this study 
is the first report of inulin-type fructooligosaccharides isolated from xylem sap of 
higher plants. The identification of inulin in maple syrup, along with its presence in 
other natural plant-derived sweeteners including agave40 and stevia,41 raises the 
possibility of this prebiotic polysaccharide contributing to the overall health benefits 
reported for these foods.   
 Ecologically, besides serving as an energy storage carbohydrate, plant cells 
regulate osmotic potential by quickly altering the degree of polymerization of inulin. 
This function allows plants to withstand cold temperatures and dehydration.42,43 This 
phenomenon also encourages future investigations on the quantity of inulin present 
in maple sap collected at various times during the tapping season to potentially 
maximize its inclusion in maple-derived food products.  
 In addition to its low caloric value, the prebiotic effects of inulin have been 
reported.19,44-46 Because inulin passes through the human upper gastrointestinal tract 
(GIT) intact, it interacts primarily with human gut microbiota. Prebiotic molecules 
such as inulin47,48 have been shown to selectively enhance the growth of beneficial 
bacteria, such as species of Bifidobacterium and Lactobacillus, while suppressing 
the growth of pathogenic strains.  
 In this study, the presence of inulin in maple syrup potentially supports an 
investigation by Cochu et al.49 who compared the growth of probiotic Lactobacillus 
sp. when using raw maple sap and sucrose as carbon sources. Results showed that 
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maple sap based media increased the viable cell counts of two strains of lactobacilli, 
Lactobacillus helveticus R0052 and Lactobacillus acidophilus AC-10, and enhanced 
their lactic acid production. This study suggested that molecules in the raw maple 
sap possess prebiotic effects and potentially provide health benefits to the GIT. 
Evidence44,46 shows that bifidobacteria and lactobacilli have different preferences for 
utilizing inulin-type fructooligosaccharides of different chain lengths. This suggests 
that despite having the same repeating unit, maple syrup-derived inulin could 
potentially have unique effects on GIT bacteria. Thus, while our finding that maple 
syrup contains inulin adds to the potential health benefits of this food, the overall 
contribution of this inulin polysaccharide remains unclear given the lack of 
supporting in vivo data. Further investigation to clarify the contributions of inulin to 
the overall benefits of maple syrup is currently being pursued by our group. 
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Figure S1. Anion exchange chromatographic profile of Fr.2. 
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Figure S2. HPSEC profile of Fr.1-1. 
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Figure S3. HPSEC profile of Fr.1-2. 
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Figure S4. HPSEC profile of Fr.2-2. 
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Figure S5. Standard calibration curve for HPSEC profiles.  
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Figure S6. HPAEC-PAD profile of neutral monosaccharide 
standards fucose, rhamnose, arabinose, galactose, glucose, 
mannose and fructose by isocratic 16 mM NaOH elution. 
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Figure S7. HPAEC-PAD profile of Fr.1-1 2M TFA 
hydrolysate of by isocratic 16 mM NaOH elution. 
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Figure S8. HPAEC-PAD profiles of fructose (top) and Fr.1-1 0.2% TFA 
hydrolysate (bottom) by isocratic 100 mM NaOH elution. 
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Figure S9. HPAEC-PAD profile of Fr.1-2 2M TFA 
hydrolysate by isocratic 16 mM NaOH elution. 
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Figure S10. HPAEC-PAD profile of Fr.2-1 2M TFA 
hydrolysate by isocratic 16 mM NaOH elution. 
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Figure S11. HPAEC-PAD profile of Fr.2-2 2M TFA hydrolysate 
by isocratic 16 mM NaOH elution. 
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Figure S12. HPAEC-PAD profiles of uronic acid standards (galacturonic acid and 
glucuronic acid) (top); Fr.1-2 2M TFA hydrolysate (middle); Fr.2-2 2M TFA 
hydrolysate (bottom). 
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Figure S13. 13C NMR spectrum of Fr.1-1 (125 MHz, D2O). 
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Figure S14. COSY NMR spectrum of Fr.1-1 (500 MHz, D2O). 
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Figure S15. HSQC NMR spectrum of Fr.1-1 (500 MHz, D2O). 
  
 
 
167 
 
Figure S16. HMBC NMR spectrum of Fr.1-1 (500 MHz, D2O). 
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Figure S17. 1H NMR spectrum of Fr.1-2 (500 MHz, D2O).  
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Figure S18. 1H NMR spectrum of Fr.2-1 (500 MHz, D2O). 
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Figure S19. 1H NMR spectrum of Fr.2-2 (500 MHz, D2O). 
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Glycosyl residue Linkage Fragmentation pattern Maple syrup polysaccharide(s) 
Rhamnosyl 2, 4 190, 203 Fr.1-2, Fr.2-2 
Arabinosyl Terminal 118, 161, 162 Fr.1-2, Fr.2-2, Fr.2-1 
 5 118, 189 Fr.1-2, Fr.2-2,  
Galactosyl 3 118, 161, 234, 277 
Fr.1-2, Fr.2-2 
Fr.2-2 
 3, 6 118, 189, 234, 305 
Fr.1-2, Fr.2-2 
Fr.2-1 
Fructosyl 2 129, 87, 161, 190 Fr.1-1 
Glucosyl 6 118, 129, 162, 189 Fr.2-1 
Galacturonic acid 4 118, 234 Fr.1-2, Fr.2-2 
Table S1. Glycosyl linkages present in Fr.1-1, Fr.1-2, Fr.2-1 and Fr.2-2. Primary 
glycosyl linkages of each maple syrup polysaccharide and their characteristic 
fragmentation patterns in GC/MS. 
 
 
